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CHAPTER I
INTRODUCTION AND AIM OF THE STUDY
Chapter 1
Introduction
Background
Radiotherapy is one of the four major treatment modalities for cancer. The others are 
surgery, chemotherapy, and to a lesser extent, immunotherapy. Hormonal manipulation of 
tumours, although not considered a treatment leading to direct kill [60], is applied as adju­
vant therapy or palliatively for breast or prostate cancer. Radiotherapy can be used as a sin­
gle modality treatment or combined with others. Radiotherapy offers excellent results not 
only for cure, but also in palliation (pain, bleeding, dyspnoe and spinal cord compression) 
[9,67].
In radiotherapy, the limiting factor is the maximal dose which is tolerated by the nor­
mal tissue. In multiple disciplines ranging from radiation physics to radiobiology and 
molecular biology, mechanisms are being investigated, how tumours can be eradicated with 
as little damage to normal structures as possible. Progress in physics allows higher tumour 
doses to be delivered with greater accuracy. Radiobiologists and molecular biologists study 
the response of the tumour and normal tissues following treatment with ionising radiation 
and the determinants of intrinsic radiosensitivity. Progress in unravelling these mechanisms 
may allow modifying the radiation response of tumours and normal tissue, ultimately 
increasing the therapeutic ratio.
Radiobiological principles.
The success of radiotherapy is dependent on several radiobiological parameters. Firstly, 
the intrinsic sensitivity of cells comprising both tumours and normal tissues to ionising radi­
ation is important. Secondly, the response of the tumour is also influenced by tumour bed 
characteristics e.g. oxygenation and temperature, which influence the fixation of radiation 
damage. Thirdly, the total tumour load, the number of clonogenic cells (i.e. the dividing 
cells, responsible for growth of the tumour) that has to be killed, determines the chance of 
achieving local tumour control [14].
The cellular response to ionising radiation determines the intrinsic radiosensitivity. This 
response consists of a cascade of reactions; the induction of DNA damage, single strand 
breaks (ssb), double strand breaks (dsb), loss or alteration of bases and cross-linking 
between DNA strands. Next the recognition of DNA damage followed by gene expression 
[72,88], the induction and/or recruitment of proteins and enzymes involved in repair of the 
DNA damage and the initiation of the machinery necessary to stop the cell cycle in order to 
give time for DNA damage repair [52,58]. Furthermore, radiation initiates a chain of reac­
tions not only in the nucleus but also in the cell membranes [11,23,34,41,53].
Intrinsic radiosensitivity can be determined by a variety of in vitro and in vivo assays. 
Clonogenic assays form the basis to establish survival curves and rank tumours according
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to their radiosensitivity. The linear quadratic (LQ) model helps to estimate radiobiological 
effectiveness of different dose-fractionation schedules with regard to acute and late toxici­
ty. Its formula contains parameters specific for a cell line or tissue and treatment-parame­
ters. [8,21,28]. The a-component represents the unrepairable DNA damage and determines 
the first part of the survival curve, while the p-component is related to the DNA damage that 
can be repaired and this component shapes the second part of the survival curve.
Cell cycle effects after radiotherapy.
Cells that grow and divide pass through a number of events, called the cell cycle. The 
cell cycle consists of four phases (Figure 1). The first part of the cycle is the G x phase, fol­
lowed by the S(ynthese) phase. During the S phase DNA is replicated; an exact copy of the 
whole genome is created in order to form two identical daughter cells. The next phase is the 
G2 phase and division takes place during the M(itose), where-after cells enter a new cycle 
(the next G1 phase). The G2 phase prepares the cell for the mitosis. During the mitosis the 
duplicated DNA strands are equally divided over the two new identical cells.
Several enzymes mediate the transition from G1 to S and from G2 to M. The S phase 
Promoting Factor (SPF) is responsible for the transition from G1 to S while the Mitosis 
Promoting Factor (MPF) thrives the cell from the S phase into the M phase. These enzymes 
consist of a catalytic subunit, the cyclin dependent kinase (cdk), and a cyclin. Cyclins are 
essential for the kinase activity of the cdk and their expression is regulated throughout the 
cell cycle. Cdk levels are constant through the cell cycle. Cells will only enter the next phase 
when all events in the previous phase have been completed. Cyclins are responsible for the 
correct order of events regulating the phases of the cell cycle.
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For an adequate repair of radiation-induced DNA damage, it is necessary that this dam­
age be recognised before division. Next, cell cycle progression and S phase should be 
slowed down in order to allow for DNA repair [46,52,58]. The biochemical pathway respon­
sible for adequate recognition of DNA damage and the consequent machinery exists of two 
checkpoints. These operate at the end of the G1 and G2 phase respectively; the so-called Gj 
and G2 checkpoints [46]. These checkpoints may be interrelated [71].
The G1 checkpoint is responsible for G1 arrest, facilitating DNA repair. p53 is essential 
in the regulation of the G1 checkpoint (see below) [10,15,27,29,49,50,54].
The G2 checkpoint checks the quality and quantity of DNA before entry into mitosis. If 
DNA damage is present, the duration of the G2 phase is prolonged. Prolonged G2 delay can 
therefore also be seen as an expression of DNA damage [68]. To accomplish a G2 delay, a 
complex interaction of cyclins and cyclin dependent kinases is necessary [46]. p53 is also 
involved in the G2 delay (see below) [40,77,90]. Inactivation of cyclin B1-associated cdc2 
kinase is essential in the p53-mediated G2/M arrest [47,70]. Based on current literature no 
clear correlation between G2 delay and radiosensitivity was found [68]. Extended G2 delay 
may lead to increased radioresistance as it allows for longer repair before division. 
Prolonged G2 delay may however also be correlated with a more radiosensitive phenotype 
as it may reflect insufficient repair damage before mitosis. If the G2 delay itself is involved 
in DNA damage repair before mitosis, then a defect in G2 delay will result in increased kill 
-mitotic catastrophe- due to unrepaired damage. These issues still need to be resolved.
The S phase delay is mediated by targeting proteins that are responsible for the DNA 
replication. p53 is not required for this. Proteins involved in initiation of DNA replication 
and elongation are part of the S phase machinery. It is suggested that the ATM gene is 
involved in the regulatory pathway to control DNA replication. AT (Ataxia Teleangiectasia) 
cells, with an inherited high intrinsic radiosensitivity, due to an aberrant ATM gene, fail to 
inhibit replicon initiation and chain elongation as a response to ionising radiation. The S 
phase delay is studied with much higher doses than the G1 and the G2 checkpoint and rela­
tive high doses are necessary to establish measurable effects. This makes the S phase check­
point a less important determinant in the cell’s radiosensitivity in clinical setting [46].
Oncogenes in Radiotherapy
Proto-oncogenes are normal cellular genes. Proto-oncogenes play a role in DNA dam­
age recognition, the regulation of checkpoints, are often involved in DNA damage repair 
[25,43,45,89] and cell cycle control [26]. Therefore it is likely that they play a role in the 
response to DNA damage caused by ionising radiation [10,15,49].
When proto-oncogenes become activated or deregulated by means of mutation, ampli­
fication or increased expression, they are called oncogenes. Activated oncogenes play a role 
in the malignant development of cells. Tumour suppressor genes prevent malignant trans­
- 10-
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formation of the cells (carcinogenesis). When tumour suppressor genes have a deficit in 
expression, by mutation or deletion, a malignant tumour may develop. For this, both alleles 
of the tumour suppressor gene must be inactivated. This is the so-called “loss of function” 
mechanism because loss of function of the tumour suppressor genes contributes to tumour 
formation.
About a decade ago, reports in the literature appeared in which expression of oncogenes 
correlated with a radioresistant phenotype [6] suggesting a common background for malig­
nant deterioration and altered radiation response. However, mechanisms of how oncogenes 
can affect the radiation response have not yet been fully elucidated in the year 2001.
The first attempt to investigate the influence of one single oncogene on radiation 
response was to compare cells that only differ in the expression of one oncogene. For these 
experiments, cells are stably transfected with the oncogene of interest. Next, experiments 
are performed in which the parental cell line serves as a control. Differences in sensitivity 
are then assumed to be solely due to the presence of the transfected oncogene. It should be 
kept in mind, however, that these tests do not explain “how” an oncogene influences radia­
tion response: one oncogene can affect multiple pathways, which may all interfere differ­
ently with the response to ionising radiation.
The most popular oncogenes studied with regard to their influence on radiation 
response are ras and myc and the tumour suppressor gene p53.
The myc oncogene is involved in the normal proliferation, transformation and differen­
tiation. It is a transcription factor and by itself not sufficient to transform cells. In normal 
cells the expression of myc is dependent on growth factors and essential for the progression 
through the cell cycle. It activates cell death by apoptosis (suicide of the cell) when over­
expressed.
The ras proto-oncogene codes for the membrane protein p21ras. The product of this 
gene has a molecular weight of 21 kDA. It belongs to the family of GTP-ases and is 
involved in the cell growth and differentiation. Whenever ras is over-expressed or mutated 
it acts as an oncogene, stimulates the activity of protein kinases and activates transcription 
of other genes like c-myc, c-fos and c-jun.
Transfections with Hras and myc oncogenes lead to increased radioresistance in rat 
embryonal fibroblasts [64,65]. This observation correlated with the stronger and longer sup­
pression of DNA synthesis after radiation [86]. However, in other systems, such as Rat-1 
cells and a human mammary epithelial cell line, transfected ras had no influence on 
radiosensitivity [3,37].
Besides the myc and ras oncogene, the p53 tumour suppressor gene has also been exten­
sively studied with regard to radiation response. The p53 tumour suppressor gene encodes 
for a nuclear phosphoprotein of 53 kDa. The protein product of this suppressor gene, wild 
type p53, plays a role in cell cycle regulation and maintaining the integrity of the genome. 
p53 protein is stabilised following DNA damage, leading to upregulation. It then binds to
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DNA in a sequence dependent manner and acts as a transcriptional activator [46]. The trig­
gers for p53 induction after radiotherapy are DNA dsbs. Other toxic events may also cause 
activation of p53 dependent pathways, such as treatment with cisplatin, hypoxia or heat 
[35,38,74,80]. p53 regulates cell cycle arrest at the end of the G1 phase [10,27,29,54] and 
is involved in the G2 delay [20,42,55,76,84,87,90]. Besides cell cycle regulation, p53 is also 
responsible for apoptosis after radiotherapy or other cytotoxic treatments [13,17,49], 
although not always obligatory [62]. The ability to undergo p53-mediated apoptosis depends 
on the cell type [66]. Detection of DNA damage and subsequent suicide of the cell are also 
mechanisms to protect “damaged” cells from malignant transformation: cells with genetic 
defects are hereby eliminated [59,81]. Wild type p53 can sense DNA damage, or direct 
repair machinery to the sites of DNA damage [7,15,48,69,73]. It consequently leads to tran­
scriptional activation of genes that contain a p53-DNA binding consensus sequence. The 
expression of p21waf1/cip1 protein (wild type p53 activated fragment) is upregulated by p53 
and this can inhibit the activity of cyclin D- and cyclin E-associated kinases [31,33,44].
Cells can die in two ways after cytotoxic treatment: mitotic death, or apoptosis. 
Apoptosis influences the low dose part of the survival curve [57]. There is no consensus 
whether apoptosis by itself determines clonogenic survival [4,63], as radiosensitivity may 
not be dependent upon the way cells die; mitotic death or apoptosis. A cell’s rescue from 
apoptosis or mitotic death can increase clonogenic survival. Arends et al. [5] transfected 
myc and mutated ras in immortalised rat fibroblasts and found that mutated ras correlates 
with reduced apoptosis (due to absence of endonuclease activity, crucial for DNA fragmen­
tation at apoptosis). This may be one explanation how ras in cells with wild type p53 can 
increase radioresistance. Vice versa, it has been suggested that when cells already have a 
reduced apoptotic response due to the presence of mutated p53, the addition of an oncogene 
like ras has less effect than in cell lines with wild type p53 (Chapter 3). The group of 
McKenna [75] also showed that inhibition of the Hras oncogene restored the apoptosis 
induction after radiotherapy in rat embryo fibroblasts. Some authors have suggested that 
p53 status could be a determinant for intrinsic radiosensitivity [13,56,57]. Although p53 
plays an important role in the response to ionising radiation, up till now no clear correlation 
between radiosensitivity and p53 status can be established [15]. It may also be possible that 
the p53 status determines whether and how expression of a certain oncogene affects radia­
tion response [1,24].
Another characteristic of p53 is its prognostic value with regard to the development of 
distant metastasis. Mutation in p53 is often predictive for a worse prognosis in a variety of 
tumours [12,19,39,51]. This may be due to an influence on local control of tumours, or by 
the increased propensity of the cells to metastasise. The better the local control, the more 
important becomes the prevention of distant metastases. Furthermore, reduction of apopto- 
sis, as seen when p53 is mutated, has been reported to be associated with an increased risk 
of distant metastases [82].
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In the seventies, it was suggested that radiation itself could influence the metastatic 
potential of tumours. However, most literature was descriptive and no molecular techniques 
were available to investigate which genes were involved in this phenomenon [85]. More 
recent literature has suggested a link between p53 and the cell adhesion molecule e-cadherin 
[16,18,22]. E-cadherin is a transmembrane glycoprotein that mediates the cell-adhesion and 
plays a role in the cell-cell contact of normal epithelium. Its presence can be detected by 
immunohistochemical techniques. Its gene maps to chromosome 16q22, and the product of 
this gene plays a role in embryogenesis and organogenesis by mediating epithelial cell-cell 
recognition and adhesion processes. Cadherins are bound to intracellular proteins, the 
catenins. E-cadherin expression can be altered or reduced in many tumours leading to 
detachment of cancer cells, facilitating the formation of metastases [30,36,78,79]. E-cad- 
herin can be seen as a tumour suppressor gene [61] with prognostic value in prostate, colon 
breast and other tumours [12,19,39,51,83]. Very recently, in vitro studies have also found 
that e-cadherin is upregulated by ionising radiation, suggesting that radiotherapy may influ­
ence the formation of distant metastases via this pathway [2,32].
Aim of the study
This study focuses on cellular mechanisms defining the radiation response of tumour 
cells. The impact of oncogene expression on radiosensitivity in human tumours is investi­
gated. Both in vitro assays, determining clonogenic cell survival, and clinical data were used 
to determine how the oncogenes MYC and RAS and the p53 status contribute to radiation 
response and outcome after radiotherapy.
For the in vitro assays, we used a melanoma cell line from human origin. Melanomas 
are known for their high radioresistance and often have mutations in the NRAS oncogene or 
overexpression of MYC. We studied whether expression of either oncogene could alter the 
radiosensitivity of the parental cell line. The next step was to determine cell cycle alterations 
in oncogene transfected cell lines in their response to ionising radiation.
For the clinical investigations, we used data of a group of patients with locally advanced 
oesophagus carcinoma who had been treated by high dose radiotherapy and followed 
prospectively. The impact of oncogene expression on the outcome of radiation treatment 
was determined.
The ultimate aim of this study is to see whether knowledge of oncogene activation 
could be a predictive factor for outcome of radiotherapy treatment, and whether it should be 
taken into account to determine the optimal treatment for patients with a malignant tumour.
The following questions served as the basis for the investigations and are discussed in 
each chapter separately.
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• Do oncogenes MYC and NRAS alter the radiosensitivity of a human melanoma cell line in 
vitro?
• What is the effect of transfection with NRAS on cell cycle response after radiotherapy?
• Is there a correlation between p53 expression and the outcome of radiotherapy treatment 
of patients with oesophagus carcinoma?
• Is e-cadherin expression related to p53 status in a group of patients with oesophagus car­
cinoma and is e-cadherin of prognostic importance in tumours treated by radiotherapy 
exclusively?
• Is the choice of antibody in the detection of p53 expression of importance in a retrospec­
tive study?
• How does cell density dependent plating efficiency affect the outcome and interpretation 
of clonogenic assays?
- 14 -
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Abstract
Activation of certain oncogenes may alter the sensitivity of cells to ionising radiation. 
We studied the effect of oncogene activation on the radiation sensitivity of cells of a human 
melanoma cell line. The cell line IGR39D was transfected with the MYC oncogene, the 
proto-oncogene NRAS, NRAS activated by a point mutation (61-arginine), or a combination 
of mutated NRAS and MYC. Single-dose experiments showed a decreased survival after 
transfection with MYC, wild type NRAS or mutated NRAS. Cotransfection with MYC and 
mutated NRAS decreased survival up to 4 Gy, whereas at higher dose no shift in radiosen­
sitivity was seen. Flow cytometry data indicated that differences in radiosensitivity could be 
explained at least in part by a difference in the distribution of cells in the phases of the cell 
cycle. After transfection of cells with either NRAS or MYC, the number of cells in Gx phase 
decreased with a concomitant increase of cells in the G2/M phase. When the cell line trans­
fected with activated NRAS was manipulated so that the distribution of the cells in the phas­
es of the cell cycle resembled that of the parental line at the time of radiation, the survival 
of the cells was improved. Similar experiments with the cell line containing MYC did not 
result in an alteration of the distribution of the cells in the cycle, or the survival after single 
dose fractions, suggesting the presence of a distinct mechanism for influencing radiation 
sensitivity. Both NRAS and MYC transfection decrease the radiation sensitivity of human 
melanoma cells, but the underlying mechanisms seem different. In conclusion, transfection 
with NRAS or MYC alone increases radiation sensitivity while transfection of cells contain­
ing NRAS with MYC restores resistance at higher doses.
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Introduction
The role of oncogene activation in radiation response has been studied extensively. 
Most studies indicate an increased radioresistance after transfection with the oncogenes 
Hras and HRAS, [10,18,23-25,27,31,34,43] Myc and MYC [9,23], ABL [14] and RAF 
[9,19,30]. The majority of publications stating that oncogenes could increase radioresistance 
have dealt with rodent systems, whereas studies with cells of human cell lines, performed 
mostly on normal tissue, have not yielded consistent results. Alteration in radiation response 
in human cell lines containing a mutated RAS oncogene, consisted of either an improved 
survival [7,9,13,14,30], or a tendency for decreased survival [1]. According to several stud­
ies, mutated RAS did not seem to alter radiation response in human fibroblasts [35], human 
keratinocytes [26] or human retinoblasts [17]. Similar data were obtained for the SRC onco­
gene in hematopoietic progenitor cells [32].
To investigate the effect of oncogene activation on the radiosensitivity of tumour cells 
of human origin, we chose a melanoma tumour cell line. Human melanomas display rela­
tively high resistance to radiotherapy. About 15% of melanomas had an activated NRAS 
oncogene (due to a mutation) [33,37] and 50% of a panel of tested melanoma cell lines has 
elevated expression of MYC [40]. For this purpose, cells of a human melanoma cell line 
without these oncogenes activated were transfected with the human MYC gene, commonly 
referred to as c-myc, NRAS, wild type or activated by a point mutation (61 arginine), or a 
combination of mutated NRAS and MYC. Clonogenic assays were used to measure survival 
after radiotherapy. Both the cell line transfected with MYC and the cell lines transfected 
with NRAS showed a decreased survival compared to the parental cell line, due in part to 
changes in distribution of cells in the phases of the cell cycle.
Material and Methods
Cell Culture and Transfection Procedures
The human melanoma cell line IGR39D, a subclone of IGR39 [3] and its transfectants 
were kept at 37°C in a 5% CO2-flushed incubator in Dulbecco’s modified Eagle’s medium 
supplemented with penicillin/streptomycin, 1.5% glutamine and 8% heat-inactivated fetal 
calf serum.
The IGR39D cell line and its MYC transfectant (IGRmyc) were described previously 
[33,40]. Briefly, an expression plasmid has been used, containing MYC exon 2 and 3 under 
the Moloney virus promotor as well as the neomycin phosphotransferase gene, which con­
fers resistance to G418 [21]. Transfection with MYC was performed using the calcium phos­
phate method [16]. Transfection with either wild type genomic NRAS or mutated NRAS 
(61-arginine) was done by the same method. A plasmid containing the wild type genomic
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NRAS or mutated NRAS (61-arginine), under the control of the CMV promotor, was trans­
fected into IGR39D cells together with the neomycin phosphotransferase gene as a selec­
tion marker [39]. The cell lines used were the IGR-R1, containing a mutated NRAS 
(61-arginine), and IGR-Q2, IGR39D transfected with wild type NRAS. We renamed these 
cell lines IGRmtras and IGRwtras. To establish a cell line with both mutated NRAS and 
MYC oncogenes, IGRmtras cells were transfected with the MYC construct together with a 
plasmid containing guanosinephosphoribosyltransferase (gpt), as a selection marker. The 
resulting cell line was named IGRras/myc. To serve as a control, the human melanoma cell 
line IGR39D was transfected with a plasmid pCMVneo, containing the neomycin 
phosphotransferase gene only (IGRneo). The used cell lines are summarised in Table 1.
RNA isolation and Northern Blotting
Northern blotting was performed as described previously to reveal the presence of ele­
vated MYC mRNA [28,40]. Briefly, cells were harvested by trypsinization and quick- 
frozen. Total RNA was isolated by the LiCl-urea method [4]. RNA (15 mg per lane) was 
fractionated by electrophoresis through a 1% agarose-formaldehyde gel and transferred onto 
nitrocellulose. Hybridization was performed sequentially with the following probes radiola­
beled by the random primer method [12]: human MYC, a ClaI-EcoRI fragment of a human 
genomic clone spanning most of exon 3 and a rat glyceraldehyde-3-phosphate dehydro­
genase (GAPDH) cDNA as a control for equal loading of RNA in each lane [41].
Protein Extraction and Western Analyses
For the detection of Myc protein, whole-cell protein extracts of cells of the melanoma 
cell line and its transfectants were prepared by high salt extraction [6,28]; 50 mg of protein 
was applied to SDS-PAGE and blotted onto nitrocellulose [8]. Immunoincubations were 
performed according to the protocol of the Western Light Kit (Tropix, Bedford MA). The
Table 1
Melanoma cell lines used in this study
IGR39D Parental human melanoma cell line with no ras mutations and no elevated
expression of MYC
IGRmyc IGR39D transfected with exon 2 and 3 of the MYC oncogene
IGRmtras IGR39D transfected with mutant 61-arg NRAS
IGRras/myc IGRmtras supertransfected with MYC IGRwtras IGR39D transfected with
wild type NRAS
IGRneo IGR39D transfected with the neomycin phosphotransferase gene only
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anti-c-myc mouse monoclonal antibody 9E10 (Cambridge Research Chemicals, Northwich, 
GB) was used at a dilution of 1:1000 [11]. Western analysis for the presence of mutated 
(61-arg) NRAS and the level of expression of wild type NRAS was performed as described 
previously [39]. Briefly, whole cell extracts were prepared using 0.14 M NaCl, 0.2 M tri- 
ethanolamine, 0.2% Na-deoxycholate, and 0.5% Nonidet P-40, supplemented with 1mM 
phenylmethylsulphonyl fluoride and 0.2 mg/ml aprotonin. Extracts were quick-frozen twice 
and centrifuged to remove debris. Immunodetection was performed using the rat mono­
clonal antibody Y13-259 [15] at a dilution of 1:400.
For both the Myc and Nras protein, second antibody incubations were carried out, using 
goat anti-mouse or goat-anti-rat conjugated alkaline phosphatase (1:2500, Promega, 
Madison WI) and the chemiluminescent substrate CSPDTM [Disodium 3-(4-methoxy- 
spiro{1,2-dioxetane-3,2’-(5’chloro)tricyclo[3.3.1.137]decan}-4-yl) phenylphosphate, Tro- 
pix] according to manufacturers’ instructions. The chemiluminescent detection of the reac­
tion product was accomplished by exposuring the membranes to Fuji RX X-ray film for
0.5-15 minutes.
Plating Efficiency
Plating efficiencies for the different cell lines were assessed. Cells were plated in 60­
mm dishes with 5 ml medium. As the plating efficiency decreased with increasing cell den­
sity, three different dilutions, each in triplicate, were plated per dose delivered. Plating effi­
ciency was 40-50% for IGR39D, IGRneo, IGRmyc and IGRras/myc cells, 20% for 
IGRmtras and 15-20% for IGRwtras cells.
Irradiation
Cells from exponentially growing cultures were harvested by trypsinization and seeded 
in 60-mm dishes, 4 hours and 18 hours before a single dose was given. Cells taken from 
confluent growth were incubated 2 hours before treatment. Cells were irradiated at room 
temperature using a 5 or 6 MV accelerator at a dose rate of 4 Gy per minute. Dishes were 
placed on build-up material and irradiated with a PA field with the iso-center in the bottom 
of the dishes at cell level. Dose per fraction was 0-10 Gy. After radiation, dishes were 
returned to the incubator. At day 10-14, colonies were fixed with 96% ethanol and stained 
with Coomassie Brilliant Blue. Colonies with 50 or more cells were counted.
Flow Cytometry
The distribution of cells in the cycle at time of irradiation was evaluated by flow cytom­
etry (FCM). Cells were trypsinized, resuspended and left to attach to the dish under the 
same conditions as cells used for radiation experiments. A total of 5x105 cells per sample 
were harvested from a 90 mm dish and kept frozen in Vindelov’s buffer [42].
Suspensions of isolated nuclei were prepared with the detergent-trypsin procedure of
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Vindelov [38,42] using propidium iodide (PI) as a DNA stain. Red blood cells from trout, 
which have about 80% of the human diploid DNA content, were added to the samples as an 
internal standard. Analysis was performed on a FACScan (Becton Dickinson, Immuno- 
cytometry Systems, San Jose, CA) equipped with a 5 W argon laser. Histograms were gen­
erated from 104 events and displayed as linear fluorescence.
Cell Synchronization
To equalize the distribution of the cells in the cycle at the time of irradiation, two meth­
ods were used, aimed at reducing the G2/M phase while increasing the G1 phase. First, cells 
were plated 18 hours instead of 4 hours before irradiation. The extended plating time result­
ed in an increase in the number of IGRmtras cells in the G1 phase concomitant with a reduc­
tion of the G2/M phase. Second, cells were grown to confluence followed by 3 days in 
serum-depleted medium resulting, both for IGRmtras and IGRmyc, in an increased popula­
tion of cells in G1 phase, while the G2/M phase was reduced.
Survival Curve
Each single-dose experiment was repeated three or four times. The mean survival per 
cell line was taken as the mean of the survival derived from three independent experiments. 
Survival curves were fitted according to the linear quadratic model using the following 
equation:
eLog S = - aD  - pD2,
where S = survival, D = radiation dose, and a  (Gy-1) and p (Gy-2) are the fitted parameters 
[5]. The nonlinear regression module of NCSA (Number Cruncher Statistical Analysis) was 
used for the computations. The standard error was calculated from the survival of all experi­
ments.
Results
Generation o f cell lines
Cells of the human melanoma cell line IGR39D were transfected with the oncogenes 
NRAS and MYC in order to establish their role in radiation response. To evaluate whether a 
difference in radiation response is specifically related to a mutation of the NRAS oncogene, 
we also transfected the wild type NRAS in the IGR39D cell line and looked for differences 
in radiation sensitivity. The oncogene Myc is known to have a minor influence on radiosen­
sitivity of rodent cell lines only, but the combination of the oncogenes Myc and Hras has 
been shown to have a synergistic effect on survival after irradiation, leading to a more 
radioresistant phenotype [25]. Therefore, we transfected the parental cell line as well as the
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cell line that contained mutated NRAS (IGRmtras) with MYC. IGR39D cells transfected 
with the neomycin phosphotransferase gene served as a control.
RNA isolation and Northern blotting were performed to establish the presence of MYC 
mRNA in the various transfected cell lines. Low endogenous MYC expression was seen in 
the parental cell line IGR39D and in the cell lines IGRmtras and IGRwtras (Figure 1A, band 
marked with star). The cell lines IGRmyc and IGRras/myc showed high levels of transfect­
ed MYC mRNA as concluded from the increase in expression of the marked band as well 
as a second (longer) transcript transcribed from the transfected construct (Fig. 1A)
Western analysis was performed to examine the presence of Myc protein. High levels 
of Myc protein were found in the cell lines IGRmyc and IGR ras/myc (Figure 1B). 
IGRras/myc cells have a lower level then IGRmyc; the latter cell line was derived by trans­
fecting IGRmtras with MYC. Much lower levels of endogenous Myc protein were detected 
in the parental cell line, IGR39D, in the NRAS-transfected cell lines IGRmtras and 
IGRwtras, and in IGRneo cells (Figure 1B).
The levels of Ras protein, wild type p21N-raswt, and mutated p21N-ras 61ARG, were also 
assayed by western analysis. The wild-type Ras protein consists of two bands, an unmodi­
fied and a farnesylated from, as indicated in Fig. 1C. The mutated protein is represented by 
one band with higher mobility. IGR39D, IGRmyc and IGRneo cells show only the wild­
type bands (Fig. 1C). In contrast, IGRmtras and IGRras/myc cells clearly show expression 
of the mutated p21N-ras 61arg . The cell line transfected with wild type NRAS shows elevated 
expression of p21wtras compared with the other cell lines.
The doubling time of IGR39D was 26 hours. IGRneo and IGRmyc showed a reduced 
doubling time (20 respectively 12.5 hours) and transfection with wild type ras lead to 
increased doubling time (33 hours). Transfection with mutated NRAS did not affect the dou­
bling time (27 hours).
Survival
The radiosensitivity of the cell lines described above was assessed by colony-forming 
assays as described in Materials and Methods. In Figure 2A the influence of transfection 
with the MYC oncogene on survival after irradiation is visualised. The IGRmyc cell line 
shows an increased radiosensitivity compared to the parental cell line. Transfection with the 
neomycin phosphotransferase plasmid pCMVneo, containing the neomycin phospho­
transferase gene only, however, did not influence the survival.
In Figure 2B the influence of transfection with either wild-type NRAS (IGRwtras) or 
mutated NRAS on radiation survival is shown. Both wild type NRAS and mutated NRAS 
lowered the survival. When the IGR39D cell line was transfected with mutated NRAS as 
well as MYC, the survival decreased in the dose range from 0-4 Gy (Figure 2C).
The radiobiological parameters a  (Gy -1) and p (Gy-2), obtained after fitting the data 
according to the linear quadratic model, as well as the 2 Gy survival (SF2) are listed in Table
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Figure 1
Expression of MYC and NRAS in transfected melanoma cell lines.
A: Northern blotting of cell lines as indicated.
B,C: Western blotting of cell lines as indicated. Antibodies against MYC (B) and p21N-ras (C), were 
used.
II. Transfection with mutated NRAS, wild type NRAS and MYC increased the a-component 
leading to a reduced shoulder of the survival curve. The effect was most pronounced in 
IGRmtras cells. Transfection of the IGRmtras cell line with MYC (IGRras/myc) also showed 
an increased a  component. The increase in a  was accompanied by a reduced SF2 (Table 2). 
Transfection with mutated NRAS, (cell lines IGRmtras and IGRras/myc) but not wild type 
NRAS or MYC, also decreased the p-component of the survival curve, suggesting a
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Table 2.
Radiobiological parameters for cells plated 4 hours before irradiation
Cell line a  (SE)a ß (SE) a/ß 2S (SE)
IGR39D 0.22 (2.10-2) 0.030 (3.10-3) 7.3 0.63 (0.061)
IGRmyc 0.36 (2.5.10-2) 0.030 (3.10-3) 12.0 0.48 (0.056)
IGRmtras 0.46 (2.5.10-2) 0.018 (3.10-3) 25.5 0.35 (0.052)
IGRras/myc 0.38 (2.4.10-2) 0.015 (3.10-3) 25.3 0.40 (0.093)
IGRwtras 0.34 (3.4.10-2) 0.045 (4.10-3) 7.5 0.37 (0.064)
IGRneo 0.17 (2.2.10-2) 0.040 (3.10-3) 4.25 0.62 (0.066)
a One standard error (SE) of the mean is given 
b 2 Gy survival fraction derived from radiobiological parameters
decreased capacity to repair sublethal damage. Wild-type NRAS increased the p-component. 
When calculating the a/p  ratio it is seen that transfection with the mutated NRAS oncogene 
(IGRmtras and IGRmyc/ras) lead to a rise in a/b ratio compared to the parental line. The 
parameters a  and p as well the SF2 for the IGRneo resemble the parental cell line IGR39D.
Distribution o f Cells in the Cell Cycle
To investigate whether the increased radiosensitivity after MYC or NRAS transfection is 
related to the phase of the cell cycle, we tested whether any changes in he distribution of 
the cells in the cycle had occurred due to transfection with the oncogenes. Cells used for 
flow cytometry underwent the same treatment as cells used for radiation experiments: 
trypsinization from cultures in 70% confluence and incubation for 4 hours. The results are 
presented in Table III, experimental setting A. A change in the distribution of the cells in 
the cycle did occur after transfection with either NRAS (mutated or wild type) or MYC. 
Compared to the parental cell line IGR39D, the G1 phase was reduced, whereas the fraction 
of cells in G2/M phase was increased. The cells transfected with either NRAS, MYC or both 
showed a slight increase in the S phase fraction.
Survival after Cell Synchronization
To test whether the difference in distribution of cells in the cycle could fully explain the 
altered radiosensitivity, cells were irradiated in the same distribution of cells in the cycle as 
the parental cell line. Earlier experiments had demonstrated, that extending plating time 
increased the G1 phase and decreased the G2/M phase of the cell line transfected with mutat­
ed NRAS. Therefore, we performed irradiation experiments with a plating time of 18 hours 
instead of 4 hours before treatment. No change in cell cycle distribution of either IGR39D,
- 31 -
Chapter 2
dose (Gy) dose (Gy)
C
Figure 2
Survival curves of melanoma cell lines.
A: IGR39D (•) , IGRneo (A) and IGRmyc (O)
B: IGR39D (•) , IGRmtras (□) and IGRwtras (V)
C: IGR39D (•) , IGRmtras (□) and IGRras/myc (■) 
The cells were irradiated 4 hr after plating.
dose (Gy)
or IGRneo cells in the cycle occurred, while IGRmyc cells showed a small reduction in 
G2/M phase (Table III, experimental setting B). Survival of either cell line was not affect­
ed (Figure 3A, 3B and 3D). The IGRmtras cell line, however, showed a more pronounced 
alteration in distribution of cells in the cycle (Table III, experimental setting B), with an 
increase in Gx phase and reduction in G2/M, concomitant with an increased SF2. In this 
case, survival was increased (Figure 3C)
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Table 3.
Experimental Setting A(1)
G1 (%) S (%) G2/M (%) SF2 (SE)a
IGR39D 68 22 10 0.63 (0.061)
IGRmyc 42 30 28 0.48 (0.056)
IGRmtras 45 27 28 0.35 (0.052)
IGRras/myc 49 27 24 0.40 (0.093)
IGR/wtras 57 25 18 0.37 (0.064)
IGR/neo 57 31 12 0.61 (0.066)
Experimental Setting B
G1 (%) S (%) G2/M (%) SF2 (SE)a
IGR39D 69 24 7 0.63 (0.078)
IGRmyc 40 40 20 0.48 (0.062)
IGRmtras 62 27 11 0.54 (0.067)
IGRras/myc ndb nd nd nd
IGR/wtras nd nd nd nd
IGR/neo 60 32 8 0.57 (0.10)
Experimental Setting C
G1 (%) S (%) G2/M (%) SF2 (SE)a
IGR39D 66 27 7 0.56 (0.098)
IGRmyc 67 21 12 0.43 (0.049)
IGRmtras 66 25 9 0.44 (0.071)
IGRras/myc nd nd nd nd
IGR/wtras nd nd nd nd
IGR/neo 67 28 5 0.57 (0.098)
(1) Experimental settings:
A: % G1 when cells are plated 4 hours before irradiation 
B: % S when cells are plated 18 hours before irradiation
C: % G2/M when cells are plated from confluent growth in serum depleted medium, 
2 hours before irradiation
a One standard error (SE) of the mean is given 
b nd: not determined
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dose (Gy)
B
0 2 4 6 8 10 
dose (Gy)
C
0 2 4 6 8 10 
dose (Gy)
D
0 2 4 6 8 10 
dose (Gy)
Figure 3
Survival curves of melanoma cell lines.
A: IGR39D plated 4 hours (0), 18 hours (O) and taken from confluent growth (A) before irradiation. 
B: IGRmyc plated 4 hours (0), 18 hours (O) and taken from confluent growth (A) before irradiation. 
C: IGRmtras plated 4 hours (0), 18 hours (O) and taken from confluent growth (A) before irradiation. 
D: IGRneo plated 4 hours (0), 18 hours (O) and taken from confluent growth (A) before irradiation.
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The second method we used to force cell lines in the same distribution of cells in the 
cycle was serum depletion of confluent cultures for three days. Cells were trypsinized and 
seeded two hours before irradiation to prevent them from entering the cell cycle before 
treatment. The distribution of cells in parental cell line IGR39D and IGRneo was not altered 
by this manipulation (Table III, experimental setting C) nor was there a change at low dose, 
but overall survival was decreased (Figure 3A, 3D). The G1 phase of the IGRmtras cell line 
increased and there was a small gain in survival at the initial part of the curve (up to 4 Gy) 
whereas survival after higher doses was comparable to the outcome of the 4-h experiments 
(figure 3C). The SF2 was slightly higher than from the 4-h experiments (0.44 vs. 0.35). 
IGRmyc with an increase in G1 phase (Table III, experimental setting C), had no increase 
in SF2 (Figure 3B). The combined experiments clearly show that prolonged plating time 
results in an increase in G1 phase, together with a decrease in G2/M phase and an increased 
survival of IGRmtras cells. Increasing the G1 phase while reducing G2/M by taking cells 
from confluent growth, however, does not lead to an expected increase in survival in the 
case of IGRmtras cells. IGRmyc cells had no clear shift in cell cycle distribution and SF2 
remained unaltered after 18 hours incubation before treatment. When IGRmyc cells were 
treated after growth in serum depleted medium, no gain in survival was seen although G2/M 
phase decreased while G1 phase increased.
Discussion
Role o f oncogenes
There is increasing interest about the role of oncogenes in the malignant transformation 
of normal cells in relation to their impact on treatment modalities. The influence of onco­
genes on survival after irradiation has attracted the attention of many radiation oncologists. 
The reports concerning an altered radiation response with oncogene expression appeared in 
the late 1980s [20,22,29,34]. These publications dealt mostly with rodent systems and indi­
cated an increased radioresistance after transfection of cell lines with the oncogenes Myc, 
Hras or Raf. Further examination of the literature for other cell types such as normal human 
cells, revealed no clear picture of the role of oncogenes in radiosensitivity. The data of the 
rodent cell lines showed consistent results, and a number of explanations for the effect of 
oncogene activation on radiation response was put forward. First, the increased radioresis­
tance of rodent cells transfected with the oncogenes Hras and Myc could be attributed to an 
increased G2-phase delay [23,36]. The G2- phase delay occurs after DNA damage to allow 
for repair before enter mitosis and is dependent on dose. Second, the distribution of cells in 
the cycle could play a role. Radiosensitivity is different for the different phases of the cell 
cycle, the G2/M phase being the most sensitive and the S phase the most resistant. Also, a 
difference in radiation response between cell lines was found to be more pronounced in the
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late S phase than in other phases of the cell cycle [10]. Third, primary rat embryo fibrob­
lasts transfected with Hras and Myc, besides showing an increased G2/M-phase delay, also 
showed prolonged inhibition of DNA synthesis resulting in a radioresistant phenotype [43].
Effects o f NRAS and MYC
Human melanoma cell lines in general are known for their radioresistance in the clinic. 
A number of activated oncogenes, including NRAS and MYC, have been found in a consid­
erable percentage of melanomas. To see whether this intrinsic radioresistance might be 
dependent on activation of these oncogenes, cells of a human melanoma cell line (IGR39D) 
were transfected with the MYC and NRAS oncogenes. We did find a different radiosensitiv­
ity after transfection with NRAS or MYC into the human melanoma cell line IGR39D. After 
transfection with the NRAS wild-type gene, with NRAS activated by a pointmutation or with 
MYC, the radiosensitivity was increased. IGRras/myc, containing both mutated NRAS and 
MYC, only showed reduced survival up till a dose of 4 Gy. To investigate whether a differ­
ence in distribution of cells in the cycle coincided with the altered radiosensitivity, analysis 
by flow cytometry was performed. Data for the parental cell line and the daughter cell lines 
transfected with mutated NRAS, MYC or both, indicated a shift in cell cycle distribution: 
Together with a decrease in the G 1 phase there was an increase in the G2/M phase. In one 
particular case (IGRmtras), we were able to partially reverse the effect of activated NRAS;
i.e., increased radiosensitivity was reversed by extending the plating time before irradiation. 
This effect is not due to a relatively increased cell number since the doubling time of 
IGRmtras was higher than that of IGRneo and IGRmyc cells. Flow cytometry showed that 
the G2/M phase had decreased while G 1 phase had increased, resembling the distribution of 
the cells in the parental cell line in the cell cycle. This indicates that, at least in the case of 
IGRmtras cell line, the increased G1 phase correlates with higher radioresistance. This phe­
nomenon does not hold for the other cell lines and is apparently associated only with 
IGRmtras.
Conditions Critical for Radiosensitivity
Starvation of the cell lines IGR39D, IGRmyc and IGRneo at confluence increased their 
radiosensitivity to doses above 4 Gy. This effect was less pronounced in IGRmtras cells. The 
treatment apparently changes processes in the cell that determine the sensitivity for ionising 
radiation. One explanation may be an increased sensitivity for radiation-induced apoptosis. 
This could be caused by activation of MYC in the serum-depleted cultures after reconstitu­
tion with complete medium. Activation of MYC is related to an increase in radiation-induced 
apoptosis and as activation of NRAS can inhibit radiation-induced apoptosis [2] this may 
explain why the survival of IGRmtras was not as strongly reduced as the other cell lines.
Finally, our data show that the time point of irradiation is of extreme importance for 
proper evaluation of the effect of NRAS, because extension of the plating time would part­
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ly have masked the effect of the oncogene (cf Fig. 3c). This stresses that experimental con­
ditions are crucial for the detection of effects of agents that influence radiosensitivity.
Conclusions
Although in rodent systems the presence of activated oncogenes, Hras and myc, is 
repeatedly associated with a radioresistant phenotype, this was not consistently observed in 
human cell lines. Our present study shows that this could not be observed for human 
melanoma cell lines, known for their radioresistance and a relatively high percentage of 
MYC and NRAS activation. We rather found an increased radiosensitivity, whereas super­
transfection of cells tranfected with NRAS restores the radioresistance, at least at higher 
doses. Most probably, MYC and NRAS affect radiosensitivity by different mechanisms, 
which in combination may interfere with each other, leading to a reduced effect of cells 
transfected with MYC as well as NRAS.
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Abstract
Background and purpose: In a previous study we found that transfection of a human 
melanoma cell line with the oncogene NRAS led to increased radiosensitivity as measured 
by clonogenic assays. Since a shift in radiosensitivity is often correlated with altered G2/M 
delay, we investigated whether this was also the case in this oncogene containing melanoma 
cell line (IGRras). Material and methods: A human melanoma cell line, stably transfected 
with mutated NRAS, and its parental cell line transfected with the neomycin phosphotrans­
ferase gene only (IGRneo), were irradiated with 5 Gy and cell cycle distribution was meas­
ured at hourly time intervals by DNA staining with propidium iodide. Next, the effect of 
ionising radiation on the duration of the S phase was determined by pulse labelling cells 
with BrdUrd before irradiation. Results: Both cell lines showed a radiation induced G2/M 
delay, which was most prolonged for the NRAS transfected cell line. After 5 Gy, the S phase 
duration was unaltered, although the shape of the relative movement (RM) curves was 
slightly different. No G 1 delay was observed in either cell line. Conclusions: NRAS trans­
fection in a melanoma cell line leads to prolonged G2/M delay after radiotherapy. This pro­
longation is associated with increased radiosensitivity and not with radioresistance. These 
data throw doubt on the use of oncogene expression or G2/M delay as predictors of 
radiosensitivity.
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Introduction
Oncogenes that are responsible for the malignant transformation and immortalization of 
cultured cells like Hras and Myc may also play a role in the response to ionising radiation. 
In literature the original work on this subject dealt with mostly rodent cell lines. A large 
amount of data has shown that when expressed in these cell lines the oncogenes Hras and 
Myc are associated with increased radioresistance [11,13,19,30]. However, some reports 
using other cell lines [1,21,24], have not confirmed this phenomenon. Furthermore the 
rodent data showed that this increased radioresistance was accompanied by an increased 
G2/M delay [18] which has also been reported for normal human diploid cell lines [32], sug­
gesting a correlation between the length of the G2/M delay and intrinsic radiosensitivity. 
This phenomenon could be a mechanistic explanation for a radioresistant phenotype since 
more time can be dedicated to repair the radiation induced DNA damage before the cell 
enters mitosis.
To further explore the relevance of this phenomenon and its impact on differences in 
radiosensitivity with regard to human tumours, a melanoma cell line was transfected with 
mutated NRAS and its impact on radiosensitivity was studied. Human melanomas are gen­
erally known as radioresistant tumours. The nature of the intrinsic radioresistance of 
melanomas remains unsolved up till now. However, it is known that a large percentage of 
these melanomas overexpress oncogenes; about 50% of human melanoma cell lines have 
elevated expression of MYC [35] and about 15% contain mutations in the NRAS oncogene 
[26,33].
Previous work of our laboratory on a human melanoma cell line did not reveal increased 
radioresistance after oncogene transfection: On the contrary the NRAS containing cell line 
was more radiosensitive [24]. The next step was to explore the hypothesis that this reduced 
survival after radiation would be accompanied by a shorter G2/M delay in the melanoma cell 
line that was transfected with the NRAS oncogene. The aim of the study was to measure cell 
cycle effects after radiation in a parental cell line which contained the neomycin phospho­
transferase gene as a selection marker only and an NRAS transfected cell line. We examined 
how cell cycle prolongation correlated with altered radiosensitivity. The results and possi­
ble mechanisms are discussed in the scope of the present literature.
Material and Methods
Cell lines
The human melanoma cell line IGR39D, a subclone of IGR39 [2] was transfected with 
mutated NRAS (61-arginine) [34]. The cell line taken from this study, IGR-R1, was
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renamed IGRras. Mutated NRAS expression was confirmed by Northern blotting for mRNA 
and western blotting for protein [24,27,34]. The neomycin phosphotransferase gene was co­
transfected as a selection marker. The cell line that contains the neomycin phosphotrans­
ferase gene only served as a control (IGRneo). All cells were kept at 37°C in a 5% CO2 
flushed incubator in Dulbecco’s Minimal Essential Medium (DMEM), supplemented with 
penicillin/streptomycin, 2.8 mM glutamine and 8% heat inactivated foetal calf serum. The 
SF2 as measured by clonogenic assays is 0.62 ± 0.06 for the parental cell line (IGRneo) and
0.35 ± 0.05 for the RAS transfected cell line (IGRras) [24].
Cell cycle alterations after radiotherapy.
To examine the shift in cell cycle distribution at different time intervals after irradiation, 
propidium iodide (PI) staining was used. Cells were irradiated with a 6 MV accelerator with 
a dose of 5 or 10 Gy. For S phase progression, cells were pulse-labelled for 5 minutes by 
adding BrdUrd (bromodeoxyuridine) at a final concentration of 1 mM to the dishes. After 
washing and replacing them in BrdUrd-free medium, the cells were exposed to 5 Gy, deliv­
ered with 250 kV at a dose rate of 0.75 Gy per minute, at ambient temperature. Cells in 
exponential growth were used. Dishes were returned to the incubator and harvested every 
hour. Cells that had incorporated BrdUrd were stained with anti-BrdUrd (a mouse antibody 
from Partec, Switzerland) and visualised using a fluorescein isothiocyanate (FITC)-conju- 
gated goat anti-mouse IgG (Sigma F-0257). Total DNA content was counterstained with PI 
and cell cycle analysis was performed on a FACScan (Becton Dickinson, San José, CA) 
using the Lysis II programme.
By labelling cells with BrdUrd, the fraction of cells in the S phase as a function of time 
post-labelling can be measured and their sequential transition through the S phase. This 
makes it possible to measure the duration of the S phase both for untreated and irradiated 
cells. The total duration of the cell cycle was also derived from these data. The relative 
movement (RM) is a measure for the transition of cells through the S phase. The RM is 
defined to be zero for cells in G1 and 1.0 for cells in the G2/M phase. The duration of the S 
phase was calculated according to the method as proposed by Begg et al. by extrapolation 
to RM equals unity, when all cells have reached G2 or beyond [6]. The relative movement 
was determined at different time intervals for irradiated and un-irradiated cultures, and used 
to determine the length of the S phase.
Results
Cell cycle alterations after radiotherapy
Figure 1 shows cell cycle alterations as a result of 5 Gy irradiation with the 6 MV 
machine. The P.I. data of the experiments performed with the 250 KV were consistent with
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A
B
C
Figure 1
Cell cycle distribution after irradiation with 5 Gy for IGRneo and IGRras (A, G1 phase; B, S-phase; 
C, G2/M phase): ▲, (neo, 5 Gy); • ,  (ras 5 Gy); A, (neo control); O, (ras control).
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the accelerator data and therefore not shown separately. In figure 1a it is seen that both cell 
lines have a decrease in Gx phase; no accumulation in G x occurs. Both cell lines reach their 
nadir at the same time (12 hours). The IGRras showed a longer nadir (12-18 hours) and 
returned back to normal slower than the IGRneo cell line (27 hours vs. 22 hours).
The S phase of both cell lines shows a small and parallel increase immediately after 
treatment with a significant drop after 12 hours (Figure 1b). This time point of 12 hours post 
irradiation coincides with the nadir of the G1 phase. At the end of the observation period the 
S phase of IGRras is not back to normal while the S phase of IGRneo is.
Both cell lines showed a G2/M delay, reflected by an accumulation in G2/M, as expect­
ed after radiotherapy (Figure 1c). This G2/M delay was dose dependent; after 10 Gy the 
G2/M delay was higher and longer for both cell lines (data not shown). The G2/M delay in 
the radiosensitive IGRras was more pronounced and longer than for the IGRneo cell line 
with a peak at 16-22 hours (IGRras) and 15 hours (IGRneo) respectively (figure 1c). The 
IGRneo had fully recovered after 30 hours while the IGRras had not reached pre-treatment 
values by 36 hours.
Both for the neo and the ras transfected cell line the time for the RM to reach unity (the 
time that all cells have moved from the S phase compartment to the G2/M phase) was the 
same (11 hours) (Figure 2a). Since the S phase percentage of either cell line was about the 
same, the cell cycle duration was not affected by transfection with the NRAS oncogene in 
untreated cells. After treatment with 5 Gy, the average slopes decreased compared with 
untreated cells for both cell lines (Figure 2b and 2c). However the difference in the slopes 
of the irradiated IGRneo and IGRras was not statistically different.
Discussion
In the present study a human melanoma cell line with increased radiosensitivity after 
transfection with mutated NRAS was tested to answer the question whether reduced survival 
correlated with altered cell cycle effects after irradiation. It was found that the radiosensi­
tive IGRras cell line showed a longer G2/M delay than the cell line containing the neomycin 
phosphotransferase gene only. Moreover, the duration of the S phase was not affected by 
transfection with NRAS and irradiation did not alter the duration of the S phase in either 
cell line.
Initial literature dealing with the relation between oncogene transfection and radiosen­
sitivity using rat embryo fibroblasts [13,19,20,25,30], described an increased radioresistance 
after transfection with oncogenes Hras and Myc. Furthermore, these resistant cells showed 
a prolonged G2/M delay [18] after radiation. It was postulated that in these cell lines the 
increased G2/M delay would lead to improved repair of DNA damage, resulting in increased 
survival after radiotherapy [12,15].
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A
B
C
Hours after labelling 
Figure 2
Relative movement at time intervals after labelling with BrdUrd for the two cell lines without irradi­
ation (A) and after irradiation with 5 Gy versus their controls (IGRneo, B; and IGRras, C).
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Based on our present observations and recent publications [22], we hypothesise that the 
prolongation of the G2 phase is merely an expression of unrepaired damage. A strong argu­
ment in favour of this hypothesis is the observation [18] that after a higher irradiation dose 
the duration and the level of the G2 phase even further increased. Moreover, ataxia telang­
iectasia (AT) cells [4,5,14], that are known for their high intrinsic radiosensitivity, show a 
prolonged G2/M delay after irradiation. Ceraline [8], using normal human fibroblasts, also 
found that increased sensitivity was accompanied by a longer G2/M delay. These observa­
tions are in agreement with data from Nagasawa et al. who observed that radiosensitive cell 
lines (human squamous cell carcinomas) responded to irradiation with a longer G2 delay 
than radioresistant cell lines, when equal doses were given [22]. However using radiation 
doses which resulted in equal clonogenic survival for all cell lines, no difference in G2 delay 
could be observed, showing the correlation between the survival and the duration of the G2 
delay.
Possible explanations for the discrepancies in literature dealing with the correlation 
between radioresistance and G2 delay can be found in the origin and characteristics of the 
different cell lines used by the different research groups. The initial data in radiobiological 
literature mainly dealt with rodent embryo fibroblasts, a non-malignant cell type, express­
ing oncogenes obligatory for embryonic development. Recent publications on the relation 
between radioresistance and cell cycle effects using human cell lines indicate that G2 delay 
did not always correlate with increased survival after radiation [3,16,29,31,36].
Warenius et al. [36] tested a panel of 12 human tumour cell lines with flow cytometry. 
In their study no clear relation between G2 delay and radiosensitivity was found. However, 
the peak of cells in late G1 accumulation, which is the G1 peak arising when the number of 
cells held in G2 /M starts to decrease, was predictive for radiosensitivity. In the present 
study, after irradiation, the number of cells in G1 phase of the IGRras cell line recovers later 
than the IGRneo cell line (Fig 1a). We believe, however, that this late Gx peak is only a 
reflection of the prolonged G2 delay; after an initial decrease, the G1 phase starts to rise 
more rapidly in the IGRneo cell line corresponding with a shorter G2/M duration. Therefore, 
a late rise in Gx would correspond with a higher intrinsic radiosensitivity.
Another important property of our cell line is that, in contrast with non-malignant 
rodent cell lines, this melanoma cell line contained mutated p53, which was probably, non­
functional due to truncation. Chiarugi et al. [9] stated that the effect of dominant oncogenes 
on radiosensitivity is dependent on the p53 status of the cell line under investigation. 
Therefore, our observation that NRAS transfection caused increased radiosensitivity might 
due to the absence of wild type p53 in this cell line. In the present study the p53 status of 
the parental cell line explains the lack of accumulation of cells in Gx Very recent literature 
has established also a role for p53 in the induction of G2/M delay [3,7,10,23,28,37]. Bache 
[3] found that a reduction in G2 delay correlated with increased apoptosis, although this 
phenomenon was not reflected in altered radiosensitivity. Guillouf [10] found that p53 was
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responsible for a more rapid exit from G2 delay, which was also correlated with increased 
levels of apoptosis. It can be suggested that cells with wild type p53 exhibit a reduced sur­
vival after radiation by increased apoptosis as a consequence of shortened G2 delay. In cell 
lines expressing Hras, the incidence of radiation induced apoptosis is reduced compared to 
the parental cell line [17] while survival is simultaneously increased. Our melanoma cell 
line of human origin contains mutated p53. Therefore transfection with the oncogene NRAS 
may not have the same relative effect with regard to apoptosis inhibition. Consequently, the 
influence of N-ras in survival can not be predicted.
Since the S phase is important for DNA damage repair, we have tested whether after 
radiation differences exist in the duration of the S phase after radiotherapy, which might 
explain the observed differences in the duration of the G2 delay. The duration of the S phase 
before treatment was exactly the same both for the ras transfected and the neo transfected 
cell line. After irradiation with a dose of 5 Gy, a small increase in the duration of the S phase 
was observed for both cell lines (Figure 2b and 2c). Also a small rise in number of cells in 
S phase is seen in the curves of Figure 1b. A possible interpretation of the shape of the 
curves (Figure 2b and 2c) is the existence of a lag period of around two hours after which 
the cell progress through S at the same rate as controls. This pattern is observed for both the 
neo and the ras cell line, and so if radiation induced differences in the duration of the S 
phase indeed occur, it will not provide an explanation for the difference in radiosensitivity.
It can be concluded that oncogenes may affect cell survival and the duration of the cell 
cycle. However, the influence of oncogenes on radiosensitivity is dependent on the origin 
and the characteristics of the cell line under investigation. Therefore, the prolongation of the 
G2/M delay or oncogene expression is not sufficient to be used as a single parameter to pre­
dict intrinsic radiosensitivity.
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Abstract
Background and purpose: Wild type p53 protein plays an important role in the cellular 
response to ionizing radiation and other DNA damaging agents and is mutated in many 
human tumours. We evaluated the relationship of the immunohistochemically determined 
p53 protein status and the disease control with radiotherapy alone for carcinoma of the 
oesophagus. Material and Methods: Immunostaining for p53 protein was performed on 
paraffin-embedded specimens from 69 patients with adeno- and squamous cell carcinoma 
of the oesophagus. All patients were treated by radiotherapy exclusively, consisting of a 
combination of external irradiation combined with intraluminal brachytherapy, using two 
different dose levels. Results: 54% (37/69) of the tumours showed overexpression of the p53 
protein. No difference in pre-treatment parameters for p53-positive and p53-negative cases 
was detected. In multivariate analysis p53 was significantly associated with Overall Survival 
(OS) next to weightloss, tumour stage and N-stage. For metastatic free survival (MFS) p53 
status proved to be the sole independent prognostic factor. The influence of p53 on local 
recurrence free survival (LRFS) however, was not as strong as on OS and MFS. 
Conclusions; Immunohistochemically detected overexpression of mutated p53 protein in 
oesophagus carcinoma, was an independent prognostic factor in a group of patients, treated 
with radiotherapy alone.
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Introduction
Treatment results of oesophageal carcinoma, with a mortality rate exceeding 80% at 2 
years, have not been improved for the last decades. In case of locally advanced disease, 
without distant metastases, radiotherapy is given with palliative or sometimes curative inten­
tion. The introduction of chemotherapy in combination with either surgery or radiotherapy 
has some advantageous effects on survival [13,14], but further studies are needed in the 
future [18]. Death in oesophagus carcinoma is mostly related to local recurrence but also to 
distant failure.
P53 is a tumour suppressor gene, encoding for a nuclear phosphoprotein of 53 kilodal- 
ton (kDa). The protein product of this suppressor gene, wild type p53 protein, plays a role 
in the genomic stability, cell cycle control and DNA damage repair after treatment with ion­
izing radiation and cytotoxic agents in fibroblasts [21,22]. After DNA damage, wild type 
p53 is responsible for the cell cycle checkpoint at the G1/S boundary, leading to cell cycle 
arrest in order to allow for DNA repair or to mediate apoptosis. Mutations in p53 lead to a 
prolonged half-life time and accumulation of the mutated protein in the nucleus. 
Furthermore the mutated p53 acts as an oncogene since accumulation of the mutated p53 
product allows cells with damaged DNA to enter the cell cycle without arrest at end of the 
G x phase [16]. As DNA repair and apoptosis are prevented, mutated p53 is suggested to play 
a role in tumorigenesis [10]. The increased mutated p53 protein product can be detected by 
immunohistochemistry. Mutations of the p53 gene have been found in many tumours and 
amongst them the oesophagus [6,11,27]. It is described as an early event in oesophageal 
oncogenesis [24]. Clinical data suggest that the expression of p53 might predict worse 
response to treatment, and can serve as a prognostic factor in tumours [19,28]. Other stud­
ies, however, did not find a negative influence of p53 overexpression on treatment outcome 
[8,15,32].
We studied a group of patients with locally advanced oesophageal carcinoma, treated by 
radiotherapy exclusively, and determined the p53 protein expression by immunohistochem- 
istry, in relationship to local control and survival.
Material and methods
Patients
At the Institute for Radiotherapy Friesland, The Netherlands, a prospective, non-ran- 
domised study was performed from 1987 to 1994, including 100 patients with inoperable 
cancer of the oesophagus. Patients with locally advanced tumours without distant metas- 
tases were treated with Radical Radiotherapy, with curative intention, consisting of External 
Beam RadioTherapy (EBRT) and Intra Luminal Brachytherapy (ILB) (patients in group I
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were treated with 50 Gy EBRT plus 15 Gy ILB, i.e. the “low dose group”, from 1987-1991 
and patients in group II were treated with 60 Gy ERBT plus 12 Gy ILB, i.e. the “high dose 
group”, from 1992-1994). Patients were prospectively scored for tumour stage, weight loss, 
dysphagia, tumour length, and histology. Tumour biopsies were obtained through 
endoscopy before treatment. Sixty-three patients had a CT scan and/or endoscopically per­
formed ultrasound, and lymphnode status was obtained. No patients were known to have 
distant metastases at the time of diagnosis. From 69 tumours of these patients (Group I; 
n=41, group II; n=28) tissue blocks fixed in 4% formaldehyde and embedded in paraffin 
were available.
Immunohistochemistry
Tumour specimens were examined with regard to p53 protein expression. P53 protein 
was detected with the aid of immunoperoxidase, according to the Streptavidin Biotin 
Complex (SAB Complex) method, using the following antibody; p53 tumour suppressor 
Protein Ab-5 (Clone DO7), a BioGenex, mouse monoclonal antibody recognising mutant 
and wild type p53. D07 is a widely used antibody for immunohistochemistry (IHC) on for­
malin/paraffin tissues.
Sections of 4 ^m thickness were cut from the paraffin embedded tissue blocks, and 
mounted on APES-coated (2% 3-Aminopropyltriethoxysilane, activated with 3% glu- 
taraldehyde) slides. Slides were dewaxed in xylene and rehydrated in decreasing ethanol 
concentration to 70%, followed by endogenous peroxidase activity blocking for 20 minutes 
in 3% H2O2 in methanol and subsequently rinsed in demineralised water. Slides were pre­
treated for 10 minutes at 90°, in 0,1M Tris/EDTA at pH 8.0 (microwave oven/450 W). After 
cooling down for at least 20 minutes the slides were washed 2 minutes in demineralised 
water, 10 minutes in PBS, pre-incubated in 1% BSA/PBS for 10 minutes, followed by 
overnight incubation with the p53 antibody DO7 (dilution 1:400 in 1% BSA/PBS). Slides 
were washed 3 minutes in PBS, followed by 30 minutes incubating with Biotine labelled 
second antibody (Rabbit-anti-Mouse, DAKO, dilution 1:800 in 1% BSA/PBS). After wash­
ing for 3 minutes in PBS, slides were incubated for 30 minutes with SAB Complex-HRP 
(DAKO), washed 2 minutes in PBS before 10 minutes visualisation using diaminobenzidine 
(DAB), washed shortly in PBS and counterstained 3 minutes in Maier Haematoxylin. 
Finally slides were washed in running tap water, dehydrated and covered. As positive con­
trols a breast- and colon-carcinoma were tested.
Analysis
The histopathologic diagnosis of each tumour was reviewed on separate HE stained 
slides. Determination of the p53 expression of tumour cells was done using a standardised 
procedure. The “tumour area” on the p53 stained biopsy slides was outlined by the surgical 
pathologist using a standard magnification of 100 x. The amount of p53 positive tumour
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cells was scored semiquantitatively during light microscopy at a 400 x magnification (high 
powerfield). Since the tissue biopsies were small, the total area of the slides was examined 
(magnification 400 x) for p53 expression. The tumour was considered positive if at least 
20% of the tumour cells expressed the protein. The level of 20% was chosen based on a 
paper by Cordon-Cordo et al [7], and also used by Wu et al [33], where it was established 
that a 20% cut-off correlates with mutations seen, when using other methods than IHC. We 
also assumed that a part of the cells would be in end Gx with elevated wild type protein. The 
p53 status was scored by 2 of the authors independently. Discrepancies were discussed until 
agreement was reached.
The correlation was studied between p53 expression and clinical parameters such as his­
tology, length of the tumour and stage. Overall survival (OS) and freedom from local recur­
rence as well as freedom from distant metastasis was calculated for both p53- and p53+ 
tumours, using the Kaplan Meier method. The log-rank test was used to test the difference 
between the curves.
In multivariate Cox regression analysis, the effects of confounders (age, sex, weightloss, 
topography, length of tumour, histology, stage and N-classification and treatment dose) on 
survival was modelled in a forward stepwise manner. Thereafter, p53 status was forced into 
the model and tested for significance.
Results
H istology and immunohistochemistry
Twenty-five tumours were squamous cell carcinomas, 43 were adenocarcinomas and 1 
tumour was classified as anaplastic. Fifty four percent of the tumours (37/69) had overex­
pression of p53 protein after staining with DO7. Of the squamous cell carcinomas 17/25 
(68%) stained positively for p53 while in the adenocarcinoma group this was 20/43 (47%). 
The anaplastic tumour showed no p53 overexpression. P53 expression was not related to 
age, sex, histology, tumour site, lymphnode status and tumour length (Table 1).
Correlation between treatment results and p53 expression
The follow up range was 2-5 years in the high dose group and 5-9 years in the low dose 
group. For statistical analysis, only the group of tumours were used of which p53 status was 
determined. Six patients are still alive without tumour, 63 are dead of whom 19 with local 
recurrence only, 15 with metastasis only, and 11 failed both locally and at distant. Eighteen 
persons have died without the presence of tumour.
When comparing the p53 negative (p53-) and p53 positive (p53+) tumours, a significant 
difference in OS (p=0.033) was seen (figure 1), with a median survival of 11,5 and 7,3 
months respectively. When stratified for total dose, the difference between p53- and p53+
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Table 1
Relationship between p53  staining and pretreatment variables.
p53 + p53- p-value
Age
s  65 years 25 21
> 65 years 12 11 n.s
Sex
Male 28 27
Female 9 5 n.s
Weightloss
No weight loss 6 10
0-5 kilo 9 8
6-10 kilo 9 4
> 10 kilo 8 7 n.s
Unknown 5 3
Topography
superior part 1 2
middle part 8 6
lower part 28 24 n.s.
Length
0-30 mm 
30-70 mm 2
 ^
<N 23
> 70 mm 11 9 n.s
Histology
squamous cell carcinoma 17 8
adenocarcinoma 20 23
anaplastic 1 n.s
Stage
I
II
4
21 23
III 5 3
IV 7 6 n.s
N-stage
N0 24 17
N+ 11 11
Nx 2 4 n.s
Treatment Dose
50 + 15 Gy 22 19
60 + 12 Gy 15 13 n.s
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Figure 1
Overall survival fo r  p53- ( -------)
and p53+  ( ---------) tumours, when
the whole group is considered.
tumours in survival remains in the 72 Gy group (p=0.047) (figure 2a), while in the low dose 
group (65 Gy) no difference in OS was found between p53+ and p53- tumours (p=0.39) 
(figure 2b). For all patients, in multivariate analysis, confounding factors of mortality were 
weight loss, tumour stage and N-stage. P53 status was still significantly associated with 
mortality (p=0.014). The unadjusted hazard rate was 1.72 ( 95% confidence interval 1.04­
2.85), and after adjustment the hazard rate was 1.96 (c.i. 1.15 - 3.31). With regard to local 
recurrence free survival, we found no influence of p53 status for the whole group (p=0.19). 
When stratified for total dose we found in the group receiving 72 Gy an indication that the 
local recurrence rate was reduced in the p53- cases compared to the p53+ cases, with a 
median local recurrence free survival of 20 and 12 months respectively. Using the log-rank 
statistic this was not significant (p=0.13), but when using the Breslow statistic, which 
weighs early events more importantly than late events, this was significant (p=0.033). Local 
recurrence free survival was not associated with the confounders in Table 1 (p > 0.06). A 
strong correlation between the development of distant metastases and p53 expression was 
found. The p53- group had a higher distant metastasis-free survival with a p-value of 0.0097 
(Figure 3). This was dose-independent. In multivariate analysis, none of the confounders 
mentioned in Table 1 was found to be related to metastasis free survival (p > 0.22), and con­
sequently p53 status was the sole independent prognostic factor.
- 63 -
Chapter 4
B 19
Months since Diagnosis 
Low Dose: 65 Gy
Figure 2
Overall survival fo r  p53- ( -------- )
and p53+  ( ---------) tumours, when
stratified fo r  high dose group (Figure 
2a) and low dose (Figure 2b).
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Figure 3
Distant metastases free survival fo r
p53- ( -------) and p53+  ( ----------)
tumours.
Discussion
P53 is a proto-oncogene, responsible for cell cycle control, growth differentiation and 
response after cytotoxic treatment. It is involved in the G1 block after radiotherapy and reg­
ulates apoptotic response [5,16]. When mutated, p53 acts as an oncogene. As a consequence 
the G1 cell cycle response after cytotoxic treatment is absent and apoptosis does not occur 
[21]. This is held responsible for the increased radioresistance, observed mostly in vitro, 
[16,20,23] although not always confirmed by others [2,29,34].
For oesophageal carcinoma, surgery is the treatment of first choice. Survival however, 
even after complete resection is very disappointing [30]. For inoperable oesophagus carci­
noma, radiotherapy with curative intention is considered for selected patients.
As the p53 gene plays a role in the response to ionizing radiation we investigated in a 
group of patients with locally advanced carcinoma of the oesophagus, treated with radio­
therapy alone, whether mutation of p53 influences treatment outcome. In vitro data strong­
ly suggest that p53 mutations lead to increased radioresistance, therefore it is of interest to 
know whether p53 status of tumours can be of predictive value for radiocurability. We 
looked at overall survival, local control and the occurrence of distant metastases. It was 
found that p53 is an independent predictive factor for the overall survival and the occurrence
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of distant metastases. The influence on locoregional control was less evident for the whole 
duration of follow up, however for locoregional failure as an early event it was a significant 
factor.
Several authors have reported about mutated p53 as a prognostic factor in oesophagus 
carcinoma, however this mostly concerned patients who underwent surgery as part of the 
treatment. While some authors found no influence of p53 on survival [25,26,31], others 
found impaired [4] or better [27] prognosis with mutated p53.
Clinical studies correlating outcome after radiotherapy with p53 status for a large series 
of tumours are reviewed in a paper by Bristow et al. [3]. It was concluded that up till now, 
it remains unclear whether p53 can serve as a predicting factor for outcome after radiother­
apy.
Several arguments for the lack of correlation between p53 status and treatment results 
for oesophageal carcinoma can be put forward. Firstly, immunohistochemically determina­
tion of the p53 status has a number of limitations; wild type p53, for example, can also show 
an increased expression which is not a feature of mutated protein in this case [12]. In con­
trast, p53 can be mutated without being detected by IHC as in the case of nonsense, splic­
ing variants and stop-codons mutations [1]. As we did not perform sequence analysis, 
indeed per sample we can not exclude that normal expression did not hide a mutation, not 
picked up by IHC or visa versa that p53 positive staining was the overexpression of abnor­
mally abundant but normally functioning protein [17]. The fixation of the archive material 
and the choice of antibodies play a crucial role too [9]. We chose D07 as this is a widely 
used antibody, so that our study is comparable to others in literature. Secondly p53 muta­
tion alone might not be enough to influence treatment outcome, as carcinogenesis is a mul­
tistep process and many more oncogenes are involved, each of them with a possible influ­
ence on treatment outcome. Thirdly, the number of patients may not be sufficiently large 
enough to determine any difference between the 2 groups. We investigated the influence of 
p53 as a predictive factor for treatment outcome after radiotherapy of oesophagus carcino­
ma. In our series, consisting of 69 patients with locally advanced tumours, immunohisto- 
chemically detection of p53 was not correlated to pre-treatment parameters. We conclude 
that in this group of patients, p53 status as determined by IHC, did not seem to predict 
radiosensitivity, but that it served as an independent prognostic factor for overall survival 
and the occurrence of distant metastases.
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Abstract
Background and purpose: E-cadherin plays an important role in the cell-cell contact of 
normal epithelium. Loss of E-cadherin expression may be related to tumour invasiveness 
and metastatic potential. In a group of patients treated for oesophageal carcinoma by radio­
therapy only, we found that immunohistochemically detected p53 expression correlated 
with reduced survival, mainly due to the occurrence of distant metastases. We questioned 
whether in this group of patients, E-cadherin expression was concomitantly altered and 
served as a predictive factor for the development of distant metastases. Materials and 
Methods: Immunostaining for E-cadherin was performed on paraffin-embedded biopsy 
specimens from patients with adenocarcinoma and squamous cell carcinoma of the oesoph­
agus. E-cadherin status and its correlation with regard to pre-treatment parameters and treat­
ment outcome were determined. Results: An aberrant staining pattern of E-cadherin did not 
correlate with any of the pre-treatment parameters. In a univariate analysis, a significant­
ly reduced metastatic potential was found for tumours that had an aberrant cellular staining 
pattern for E-cadherin, which was strongest for squamous cell carcinomas. However, in a 
multivariate analysis only p53 status correlated significantly with the occurrence of distant 
metastases. Conclusion: Although in univariate analysis, aberrant E-cadherin expression 
served as a better, rather than a worse prognostic factor, p53 status remained the only sig­
nificant parameter in multivariate analysis, in this group of patients with oesophageal carci­
noma. No relationship between p53 status and E-cadherin expression was found.
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Introduction
E-cadherin is a transmembrane glycoprotein that mediates cell adhesion and plays a 
role in the cell-cell contact of normal epithelium [1]. Its presence can be detected by 
immunohistochemical techniques. Its gene maps to chromosome 16q22, and the product of 
the gene is involved in embryogenesis and organogenesis by mediating epithelial cell-cell 
recognition and adhesion [8,12]. Cadherins are bound to intracellular proteins, the catenins 
[1,3,4]. E-cadherin expression is altered or reduced in many tumours leading to detachment 
of cancer cells, facilitating the formation of metastases [4,10].
In one study [6], it was found that premalignant skin lesions in p53-knock out mice 
showed alterations in E-cadherin expression, while this was rarely the case in tumours with 
heterozygote or wild type p53. Another clinical study [5] showed an association between 
down regulation of E-cadherin expression and alteration in p53 in a series of 210 breast car­
cinomas, suggesting that p53 could play a role in the regulation of E-cadherin expression. 
A further study [7] also found a correlation between reduced E-cadherin expression and 
positive p53 staining in breast carcinomas. Two recent papers have shown that radiation may 
increase E-cadherin expression in human tumour cell systems [2,9], suggesting that radia­
tion may influence the metastatic behaviour of tumours. In a recent study in oesophageal 
carcinoma treated exclusively with radiotherapy, we found that p53 overexpression was cor­
related with reduced overall survival and the increased occurrence of distant metastases 
[16].
We therefore questioned whether E-cadherin could be a prognostic factor for tumours 
treated by radiotherapy, and whether this is related to p53 status, indicating a possible func­
tional link between E-cadherin and p53 status in radiation response. As a model we took 
oesophageal tumours, irradiated with high dose. In this group of patients, p53 status had 
been shown to correlate with overall survival (OS) by increased distant metastases.
Material and methods
Patients
In a group of 65 patients with locally advanced carcinoma of the oesophagus treated 
between 1987 and 1994 by radiotherapy only, paraffin embedded archival material from 
pre-treatment biopsies, obtained by endoscopic procedures was available to test the E-cad- 
herin expression by immunohistochemistry.
The radiotherapy consisted of external radiation to 50 Gy (from 1987-1992) or 60 Gy 
(from 1992-1994), with an intraluminal boost of two times 7.5 Gy or 2 times 6 Gy respec­
tively. The opinion, based on literature, that 50 Gy was insufficient to treat the regional 
lymph nodes adequately lead to an increase of the external dose delivered, with a concomi-
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tant reduction of the brachytherapy dose to avoid acute and late toxicity. All patients had 
locally extensive disease without distant metastases and were suitable to undergo high dose 
radiotherapy. All patients were prospectively followed and questionnaires were filled-out 
every visit.
Immunohistochemistry.
E-cadherin expression of the tumour specimens was detected by immunohistochem­
istry and visualised using the Streptavidin Biotin Complex (SAB Complex) method. The 
monoclonal mouse anti-E-cadherin antibody HECD-1 (Takara, Berkeley, CA) was used at a 
dilution of 1:400.
Section of 4 ^m were cut from the paraffin embedded tissue blocks, and mounted on 
APES-coated slides (2% 3-Aminopropyltriethoxysilane, activated with 3% glutaraldehyde). 
Slides were dewaxed in xylene and rehydrated in decreasing ethanol concentration to 70%, 
followed by endogenous peroxidase activity blocking for 20 minutes in 3% H2O2 in 
methanol and subsequently rinsed in demineralised water. Slides were pre-treated for 10 
minutes at 90°, in 0,1M Tris/EDTA at pH 8.0 (microwave oven/450 W). After cooling for 
at least 20 minutes the slides were washed for 2 minutes in demineralised water, 10 minutes 
in PBS, pre-incubated in 1% BSA/PBS for 10 minutes, followed by overnight incubation 
with the antibody HECD-1 (dilution 1:400 in 1% BSA/PBS). Slides were washed 3 min­
utes in PBS, followed by 30 minutes incubation with biotine-labelled second antibody (rab­
bit-anti-mouse, DAKO, dilution 1:300 in 1% BSA/PBS). After washing for 3 minutes in 
PBS, slides were incubated for 30 minutes with horseradish-peroxidase-linked streptavidin- 
biotin complex (DAKO), and washed for 2 minutes in PBS. To detect the labelling, incuba­
tion for 10 minutes with diaminobenzidine was used. After the slides had been washed 
briefly in PBS, they were counterstained for 3 minutes with Mayer Haematoxylin. Finally 
the slides were washed in running tap water, dehydrated and covered.
Analysis
The whole biopsy area as presented on the slide was scored for E-cadherin expres­
sion in the areas containing the malignant cells. E-cadherin staining was scored as normal 
or abnormal (N/A). Cytoplasmic, apical, aberrant, absent and basal staining of tumour cells 
were considered abnormal. If at least 10% of the cells expressed E-cadherin in this way, 
the tumour was considered to have an abnormal staining pattern [17,19]. Staining of the lat­
eral plasma membrane was considered normal. Non-malignant epithelium assessed on the 
same slide served as an internal control.
E-cadherin expression was correlated with clinical parameters such as age, sex, weight 
loss, topography, length of tumour, histology, p53 status, stage and N-classification. Overall 
survival and freedom from local recurrence as well as freedom from distant metastases were 
assessed for tumours with normal versus abnormal expression of E-cadherin, using the
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Kaplan-Meier method. The log-rank test was used to test for the differences.
In a multivariate Cox regression analysis, the effects of confounders (age, sex, weight 
loss, topography, length of tumour, histology, grade, stage, p53 status, N-classification and 
treatment dose) on survival was modelled in a forward stepwise manner.
Results
Patients
At the time of evaluation with a follow up period of 1-6 years, 6 patients were still alive 
(more than 3 years), and 59 had died of whom 18 with local recurrence only, 13 with dis­
tant metastases only and 10 with both local and distant failure. Eighteen patients had died 
without tumour.
Analysis
Fifty-one tumours (78%) expressed E-cadherin abnormally while 22% showed normal 
expression of E-cadherin on the lateral plasma membrane. In Table 1 the correlation of the 
pre-treatment parameters with the expression of E-cadherin is shown. E-cadherin expression 
did not correlate with any of the 11 pre-treatment parameters tested.
E-cadherin expression did not predict the outcome of treatment with regard to local 
recurrence-free survival or overall survival (Table 2). However, distant metastases occurred 
less frequently when E-cadherin was expressed abnormally (Figure 1, p=0.033): The rela­
tive risk was 2.47 (95 % c.i. 1.05-5.8). After correcting for the pre-treatment p53 status as 
a confounder, the relative risk was reduced to 1.45 (95% c.i. 0.52-4.09). The only signifi­
cant prognostic factor in multivariate analysis was the p53 status (p=0.037). Stratification 
according to tumour histology (adenocarcinoma versus squamous cell carcinoma) showed 
that abnormal E-cadherin expression correlated significantly with a longer metastatatic free 
period (MFP) for squamous cell carcinomas (p=0.0256). In the group of adenocarcinomas 
the influence of E-cadherin expression on MFP was not significant (p=0.29) (Figure 2a and 
2b). Overall survival in both histology groups was not influenced by the E-cadherin status.
The total dose delivered neither influenced the disease free survival (p=0.99) nor the 
distant metastases free survival (p=0.98). The effect of E-cadherin expression on survival 
without distant metastases was also the same in both dose groups.
Discussion
In a previous study it was found that p53 positive oesophageal tumours treated by 
radiotherapy meant a significantly reduced overall survival, which was due to the increased
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Tabel 1
Correlation between e-cadherin expression and pre-treatment parameters
Abnormal expression Normal expression
(n=51) (n=14)
Adenocarcinoma 30 (59%) 10 (71%)
P53 positive 23 (46%) 8 (73%)
Grade III 30 (60 %) 4 (29%)
Stage I,II 35 (69%) 11 (78%)
Total Dose 72 5 (10%) 2 (14 %)
Age (mean) 69 yrs (+/- 9) 67 yrs (+/- 10)
Nodal stage N+ 19 * (37%) 4 (29%)
Nodal stage NO 27 (54 %) 9 (64 %)
Nodal stage Nx 5 (10%) 1 (7%)
Male 41 (80%) 13 (93%)
Upper third 3 (6%) 0 (0%)
Middle third 11 (22%) 4 (28%)
Lower third 37 (72%) 10 (71 %)
Length (mean) 64 mm (+/- 25) 64 mm (+/- 22)
Weightloss (mean) 4.9 Kg (+/- 4.7) 7.0 (+/- 8.0)
No difference was statistically significant.
Figure 1
Distant metastases free survival when E-cadherin stains normal ( -------- ) or
abnormal ( -------) (p<0.05).
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Figure 2
Distant metastases free survival when E-cadherin stains normal ( -------- ) or
abnormal ( -------) for squamous cell carcinomas (Fig. 2a) or Adenocarcinomas (Fig 2b)
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Table 2
E-cadherin expression and treatment outcome
a
(n=51)
n
(n=14) P*
Survival: % (SE) 6 mths 61 (7) 79 (11) 0.91
1 year 31 (7) 50 (13)
RFP: % (SE) 6 mths 67 (7) 73 (13) 0.91
1 year 57 (8) 55 (15)
RFS: % (SE) 6 mths 45 (7) 62 (13) 0.68
1 year 24 (6) 23 (12)
MFP: % (SE) 6 mths 78 (6) 69 (13) 0.033
1 year 71 (8) 52 (14)
MFS: % (SE) 6 mths 55 (7) 62 (13) 0.96
1 year 27 (6) 46 (14)
DFS: % (SE) 6 mths 41 (7) 46 (14) 0.98
1 year 22 (6) 23 (12)
* p value of Student’s t-test, Pearson chi-square, or logrank test, where appropriate.
a: abnormal expression 
n: normal expression
RFP (relapse free period), RFS (relapse free survival), MFP (metastasis free period) MFS 
(metastasis free survival) DFS (disease free survival)
occurrence of distant metastases [16]. Since E-cadherin is a marker for tumour invasiveness 
and the occurrence of distant metastases, we investigated whether E-cadherin expression 
was related to pre-treatment parameters, including p53 status and whether it could also 
serve as a prognostic factor. No correlation of E-cadherin expression with any of the pre­
treatment parameters tested, including p53 status, was found. A reduced probability of dis­
tant metastases was found in cases showing an aberrant staining pattern of E-cadherin. 
Stratifying according to histology showed that this was significant for squamous cell carci­
nomas. In a multivariate analysis, only p53 correlated significantly with the development of 
distant metastases and overall survival.
Reduced expression of E-cadherin in oesophageal carcinoma has been described before, 
and correlated with high stage, high histological grade and reduced survival [14,15,18]. The 
worse prognosis with reduced E-cadherin expression was often explained by the elevated
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risk of distant metastases when cell-cell contact is disturbed. Only one study [11] found an 
opposite relationship between abnormal E-cadherin expression and the occurrence of liver 
metastases in pancreatic tumours, i.e. the cells that expressed E-cadherin normally had 
increased chance to form metastases.
We found that abnormal E-cadherin expression correlated with distant metastases only 
for squamous cell carcinomas. A similar result has been published previously [13] although 
in that paper absent E-cadherin expression served as a worse prognostic factor. To explain 
the inconsistent correlation between immunohistochemically detected E-cadherin expres­
sion in tumours and the development of distant metastases, several arguments can be put 
forward. First, the terminology used for the immunohistochemical expression of E-cadherin 
is not consistent throughout the literature; either the level of expression is looked at (normal 
versus reduced) or both the level and the localisation (abnormal versus normal expression). 
Although in theory detachment of cancer cells would be facilitated by abnormal E-cadherin 
function, normal expression may be necessary in order to establish metastases [11].
E-cadherin expression can be increased by radiation, as described in recent papers [2,9]. 
If so, and if E-cadherin is also involved in the establishment of distant metastases, it may be 
hypothesised that radiotherapy may influence metastatic potential of tumour cells during 
treatment. This could be another possible explanation why E-cadherin can be of different 
prognostic importance in tumours treated by radiotherapy only, compared to tumours that 
are treated surgically.
The concept that ionising radiation may modify metastatic potential of tumours is not 
new. In a review by von Essen [20], the influence of local radiotherapy on the occurrence 
of distant metastases, both in vivo experiments and clinical data are extensively described. 
These are all mostly descriptive papers, however, and no study correlating radiotherapy and 
distant metastases looked for gene or protein expression that can mediate this phenomenon 
. In a multivariate analysis, only p53 status correlated with distant metastases. Any E- 
cadherin effect, therefore, could be masked by the p53 status. Although we found no corre­
lation between p53 status and E-cadherin status, this study can not rule out a direct influ­
ence of p53 on E-cadherin expression.
So far one study in rodents [6] has shown a, presumably functional, correlation between 
the p53 status and E-cadherin expression and two clinical studies have found a correlation 
between p53 status and E-cadherin expression [5,7].
In summary, we found in a group of 65 patients treated by high dose radiotherapy for 
locally advanced oesophageal carcinoma that aberrant expression of E-cadherin correlated 
with reduced occurrence of distant metastases, particularly for squamous cell carcinomas. 
In multivariate analysis, however, only p53 status correlated with the occurrence of distant 
metastases. We could not establish a relationship between p53 status and E-cadherin expres­
sion in this series.
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Abstract
Background and purpose; Wild type p53 protein plays an important role in the cellular 
response to ionising radiation and other DNA damaging agents and is mutated in many 
human tumours. Immunohistochemistry is a rapid method to detect elevated protein levels. 
The p53 status in a group of patients treated by radiotherapy exclusively for oesophagus car­
cinoma was examined and correlated with pre-treatment parameters and treatment outcome 
with regard to overall survival, local recurrence free survival and distant metastases free sur­
vival. In this paper, four different antibodies were used to evaluate their predictive power 
detecting p53 expression. Material and Methods; Immunostaining for p53 protein with 4 
different antibodies was performed on paraffin-embedded specimens from 69 patients with 
adenocarcinoma and squamous cell carcinoma of the oesophagus. All patients were treated 
with radiotherapy exclusively, consisting of external irradiation combined with intraluminal 
brachytherapy. Results; Detection of p53 using the antibody (DO7) was significantly cor­
related with overall survival and distant metastases free survival. For local recurrence free 
survival no statistical significance was reached. The use of the other 3 antibodies all showed 
the same trend with regard to distant metastases, however statistical significance was never 
reached. The use of multiple antibodies did not increase the predictive value of DO7. Both 
for survival and metastases free survival the use of DO7 alone was sufficient as a signifi­
cant prognostic factor. We conclude that in this series, only the use of DO7 was correlated 
with prognosis in oesophagus carcinoma treated by radiotherapy only and that addition of 
3 antibodies did not improve the predictive power.
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Introduction
P53 is a tumour suppressor gene, encoding for a nuclear phosphoprotein of 53 kilodal- 
ton (kDa). The protein product of this suppressor gene, wild type p53 protein, plays a role 
in the genomic stability, cell cycle control and DNA damage repair after treatment with ion­
ising radiation and cytotoxic agents [14,15]. It is involved in the Gx block after radiothera­
py and regulates apoptotic response [3,11]. When mutated, p53 acts as an oncogene. As a 
consequence the G1 cell cycle response after cytotoxic treatment is absent and apoptosis 
does not occur [13]. This could explain the increased radioresistance as observed mostly in 
vitro, [11,12,16] although not always confirmed by others [2,21,26]. Mutations of the p53 
gene have been found in many tumours and amongst them the oesophagus [4,7,19]. 
Elevated protein level, which occurs in case of mutations, can be detected by immunohis- 
tochemistry (IHC). However IHC has a number of limitations and its sensitivity is estimat­
ed only to be 75% and the predictive value is only 63% [23]. We studied a group of patients 
with locally advanced oesophageal carcinoma, treated by radiotherapy exclusively, and 
determined the p53 protein expression by immunohistochemistry, using four different anti­
bodies to investigate whether their combination would increase their predictive power with 
regard to overall, local recurrence and distant metastases free survival.
Material and methods
Patients
A group of 69 patients with locally advanced carcinoma of the oesophagus, treated by 
radiotherapy exclusively, was subject of investigation. No patients were known to have dis­
tant metastases at the time of diagnosis. From the tumours of these patients paraffin embed­
ded archival material was available detect p53 expression by immunohistochemistry.
Antibodies.
P53 protein expression of the tumour specimens was detected with the aid of the 
immunoperoxidase method, according to the Streptavidin Biotin Complex (SAB Complex) 
method [17], using the following antibodies: Antibody BP53-12, mapping N-terminus aa. 
20-25; Antibody clone PAb 1801, mapping aa. 32-79, and Ab-5 (Clone DO7), mapping aa 
37-45. These antibodies (from Neomarkers, Fremont CA) react with wild type and mutant 
p53. The fourth was clone CM-1, a polyclonal rabbit antibody reacting with wild type and 
most mutant forms of p53 (Biogenx, San Ramon, CA). The size of the archival slides did 
not permit staining with all 4 antibodies for all cases: Sixty-nine slides were stained with 
the antibody 1801 while in 68 cases the p53 expression was determined by DO7, in 67 cases 
by PB 53-12 and 64 times by CM1.
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Analysis
After staining, all slides were scored by two of the authors (CK and JP). Discrepancies 
were discussed till agreement was reached. Specimens were considered to be positive for 
p53 expression when at least 20% of the tumour cells were stained [5].
The concordance between the different antibodies used for testing p53 expression is 
described. Furthermore the correlation for each antibody separately, was studied between 
p53 expression and clinical parameters such as age, sex, weightloss, topography, length of 
tumour, histology, stage and N-classification. Overall survival (OS) and freedom from local 
recurrence as well as freedom from distant metastases was calculated for both p53- and 
p53+ tumours, using the Kaplan Meier method. The log-rank test was used to test the dif­
ference.
In multivariate Cox regression analysis, the effects of confounders (age, sex, weightloss, 
topography, length of tumour, histology, stage and N-classification and treatment dose) on 
survival was modelled in a forward stepwise manner. Thereafter, p53 status, as determined 
by each antibody separately, was forced into the model and tested for significance.
Results
Patients
At the time of evaluation with a follow up period of 2-9 years, 6 patients were still alive, 
and 63 had died of whom 19 with local recurrence, 15 with distant metastases only and 11 
with both local and distant failure. Eighteen patients had died without tumour.
The 4 different antibodies used
In 61 of the total cases the expression of all 4 antibodies was determined; not all biop­
sies contained enough tumour to sufficiently estimate the staining of 4 antibodies. Eighteen 
times the slides were negative using 4 antibodies and 19 scored positive using 4 antibodies. 
In seven, eight and nine cases, 1,2 and 3 antibodies stained positive respectively. A good 
concordance (p<0,0001) existed between the expression of 4 antibodies tested; the correla­
tion coefficients were 0.51 or more.
Correlation between pre-treatment parameters and p53 expression
No correlation between pre-treatment parameters like histology (adenocarcinoma, squa­
mous cell carcinoma), length of tumour, topography, lymphnode status, stage, age and 
weightloss, for either antibody tested was found (p>0.5) except for the CM1; This antibody 
detected p53 expression significantly more in case of squamous cell carcinoma ( 18/25, P=
0.003).
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Correlation between treatment outcome and p53 expression
Of the four antibodies tested, only the use DO7 in the detection of p53 expression cor­
related significantly with disease fee survival. (Table 1). This was due to a significant lower 
occurrence of distant metastases in the group of tumours that stained negatively for DO7. 
Time to local recurrence for DO7 negative tumours was longer than for D07 positive 
tumours, but this did not reach statistical significance. The other antibodies showed no cor­
relation with either local or distant failure, although for 1801 a trend exists for p53 negative 
tumours having longer distant metastases free period.
Discussion
We tested whether immunohistochemically determined p53 expression could correlate 
with treatment outcome in a group of patients treated with radiotherapy for oesophagus car­
cinoma. In a previous study it was found that expression determined by the antibody DO7 
strongly correlated with overall survival and distant metastases free survival [17]. To inves­
tigate whether the addition of more antibodies would increase the predictive value, four dif­
ferent antibodies were used. The other 3 antibodies, although showing the same trend, were 
not significantly correlated with treatment outcome. The addition of 3 extra antibodies to 
DO7 did not increase the predictive value (p>0.58).
P53 is an oncogene, mutated in many malignant tumours of different organs including 
the oesophagus. As it plays a role in the response to cytotoxic treatment, like ionising radi­
ation, it might serve as a predictive factor for treatment outcome. Immunohistochemistry, 
revealing elevated levels of the p53 protein is a rapid way to determine overexpression of 
p53, which is assumed to correlate with mutations in the gene. However, immunohisto- 
chemical determination of the p53 status has a number of limitations [23]; wild type p53, 
for example, can show an increased expression [8] or p53 can be mutated without being 
detected by IHC [1]. The fixation of the archive material and the choice of antibodies, which 
is subject to variation plays a crucial role too [6,22]. Serbia [18] found no correlation with 
survival using D01 (67% stained positive), in a group of 204 patients having surgery for 
squamous cell carcinoma of the oesophagus.
Horne [9] compared the same four different antibodies for immunohistochemistry as we 
did, when looking at p53 as a prognostic factor in breast carcinoma; PAb1801, p53-BP-12, 
DO7 and CM1. It was concluded that Pab 1801 and DO7 were the most effective. However 
in their series the use of 1801 showed the strongest prediction for prognosis. Vet et al [24] 
tested the differences between IHC and single strand conformation polymorphism (SSCP) 
in bladdercarcinoma. They found a good concordance between SSCP and IHC. But it was 
noticed that p53 stability (leading to overexpression of p53 protein) was not merely trig­
gered by mutation. This means that p53 staining can be positive while the protein is wild
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Table 1
Median disease free survival, metastasis free period, and local recurrence free period 
(95%confidence interval) and the associated relative risk (95% confidence interval) for 
each o f the 4 mutations.
Negative Positive P#
Disease Free Survival (months):
1801 median 11 (7-16) 7 (6-9) 0.29
Relative Risk 1.32 (0.79-2.20)
DO7 median 12 (6-19) 7 (2-12) 0.03
Relative Risk 1.73 (1.04-2.89)
PBP 53-12 median 9 (0-18) 8 (4-12) 0.43
Relative Risk 1.23 (0.74-2.04)
PCM1 median 8 (5-10) 10 (6-15) 0.79
Relative Risk 0.93 (0.55-1.57)
Metastasis Free Period (months):
1801 median >25* 14 (5-23) 0.61
Relative Risk 1.24 (0.54-2.88)
DO7 median >25* 10 (7-14) 0.006
Relative Risk 3.29 (1.35-8.00)
BP 53-12 median >14* 14 (7-21) 0.16
Relative Risk 1.86 (0.78-4.42)
PCM1 median 25 (0-63) >14* 0.78
Relative Risk 0.89 (0.38-2.06)
Local Recurrence Free Period (months):
1801 median 13 (6-19) 15 (7-22) 0.82
Relative Risk 1.09 (0.52-2.30)
DO7 median 14 (9-19) 10 (4-16) 0.23
Relative Risk 1.55 (0.75-3.21)
BP 53-12 median 13 (7-19) 15 (5-24) 0.79
Relative Risk 1.10 (0.54-2.27)
PCM1 median 13 (6-20) 15 (-)** 0.67
Relative Risk 0.85 (0.39-1.84)
* The median could not be estimated, it was larger than the largest time at which an 
event occurred.
** The 95% confidence interval could not be estimated.
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type. Jacquemier et al. [10] tested 4 different antibodies in breast cancer (1801, 240, DO7 
and DO1). While 40% of the tumours had at least 1 antibody positive, only 14% scored pos­
itive for all antibodies used. After performing SSCP on a selected group of specimens it was 
concluded that p53 overexpression was not representative for the number of cells with a 
mutation. Furthermore in their series of breastcarcinoma, p53 status, determined by either 
procedure was not correlated with disease free survival (DFS) or early recurrence. Xu et al. 
[25] using 3 different antibodies (Pab421, Pab240 and Pab1801) in head and neck cancer 
found large differences in immunopositivity (varying from 32 to 53 %). In contrast with Vet 
et al, in their series, SSCP results correlated poorly with p53 expression as determined by 
IHC. As an explanation for false positive and false negative IHC findings, nonsense and 
frameshift mutations are put forward. Schneider et al [20] pointed out that the discrepancy 
between IHC and SSCP varies amongst tumours.
We conclude from our series, that the use of DO7 for the detection of p53 expression, 
served as a good indicator for prognosis in a group of patients with locally advanced 
oesophagus carcinoma. It was strongly correlated with the occurrence of distant metastases. 
The additional use of 3 other antibodies did not increase its predictive value with regard to 
prognosis.
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Abstract
Background and purpose: The usefulness of colony forming assays (CFA) has been 
established for almost 40 years [8]. Although time consuming and not successful for all cell 
lines, it is generally considered to be the gold standard of assays for testing the sensitivity 
of cell lines to ionizing radiation or other cytotoxic agents in vitro. We recently found for 
several cell lines that the plating efficiencies of both control and irradiated cells is depend­
ent upon the density of cells seeded for colony formation; that is, increasing cell inoculum 
levels resulted in a non-linear relationship with colony formation, even at relatively low 
colony numbers. Material and methods: All data from a human melanoma cell line, trans­
fected with c-myc or N-ras as well as from normal human diploid fibroblasts were taken to 
see how this phenomenon influenced outcome and interpretation of clonogenic assays. 
Survival was recalculated using all data, or only data with a linear relationship between 
inoculum level and colony formation. Results: It is found that when data with a non-linear 
relationship between inoculum level and colony formation are included, survival can be 
underestimated due to inhibition of colony formation in treated cultures. Conclusion:  For 
validity, colony forming assays must be standardized to assure a constant relationship 
between the cell density and colony forming efficiency. This usually requires a much lower 
density of colonies than has been typically published for many cell survival studies.
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Introduction
Colony forming assays (CFA) are used to determine the fraction of cells that survive 
after in vitro cytotoxic treatments (eg. irradiation). Cell survival is defined as the ratio of the 
plating efficiencies (PE), (i.e. the percentage of cells seeded that grow into macro colonies) 
between treated and untreated cells. When determining PE, the assumption is commonly 
made that PE is independent of the number of cells seeded into culture, at least over a wide 
range of cell numbers. For statistical reasons, cells are generally seeded to obtain a rela­
tively constant number of surviving macro-colonies in each culture dish, typically ranging 
from 25 to 200 colonies. To accomplish this, the number of cells seeded must increase with 
the treatment dose. This approach is valid, of course, only if colony formation is independ­
ent of cell seeding density. While investigating the role of oncogene transfection on radia­
tion sensitivity of a human melanoma cell line (IGR39) (Pomp et al, submitted for publica­
tion) [7], we found that the plating efficiency of the parental line and all of its derivatives 
was not constant with respect to the number of seeded cells. This was found to be true in 
both untreated and radiation treated cultures. Higher cell inocula resulted in the formation 
of fewer that expected colonies. This cell density dependent PE was not restricted to malig­
nant or normal cells and was also independent of the presence or status of transfected onco­
genes. The objective of this study was to examine for the occurrence of a non-linear rela­
tionship between colony formation and seeding density in cell lines of various origins and 
to determine the effects on cell survival measurements.
Material and Methods
Cell lines
The human melanoma and fibroblast cell lines were kept at 37°C in a 5% CO2-flushed 
incubator in DMEM supplemented with penicillin/streptomycin, 1.5% glutamine 
(melanoma cell lines) and 8% heat-inactivated fetal calf serum (melanoma cell lines) or 
15% fetal bovine medium serum (human fibroblasts).
The human melanoma cell line IGR39D derived from IGR39 [1] and its transfectants 
are described elsewhere [6,9]. Briefly, this melanoma cell line was transfected with the 
oncogenes c-myc (IGRmyc) and mutated N-ras (61-Arginine)(IGRras). A cell line trans­
fected with the neomycinphosphotransferase resistance gene, conferring resistance to G418, 
was used as a control (IGRneo).
Normal skin fibroblast cultures, all in early passage, were derived from a group of 
patients that are part of an ongoing study, determining the relationship between the survival 
at 2 Gy (SF2) and late reaction after radiotherapy for breast cancer. The data from two 
strains with different radiosensitivities were used to calculate SF2. These were designated
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Figure 1
D ensity dependent p lating effi­
ciency in human skin fibroblasts. 
Colony numbers exceeding 70 
colonies p e r  dish are no longer 
linear with the number o f  cells 
seeded.
BAR1 (SF2 = 0.24), and S33 (SF2 = 0.45). The data from all of these cell lines were used 
to compose Figure 1.
Plating efficiency
Plating efficiencies for the different cell lines were assessed. For human melanoma cell 
lines, plating efficiencies ranged from 20-50% and for human fibroblasts from 3-60%. 
Exponentially growing or confluent cultures were made into single cell suspensions, 
checked for multiplicity, seeded into culture dishes (60 mm for melanoma cells and 100 mm 
for fibroblasts), and incubated at 37° with 5% CO2 in air. Melanoma colonies were fixed 
with 96% ethanol and stained with 0.4% Coomassie Brilliant Blue. Fibroblast colonies were 
fixed with 70% ethanol and stained with 0.5% crystal violet. Melanoma colonies were fixed 
after two weeks in culture and fibroblast colonies were fixed at variable times, depending 
upon their growth rate. Colonies containing 50 or more cells were scored as survivors.
Irradiation protocol
Cell suspensions from three human melanoma cell lines cells (IGRneo, IGRmyc and 
IGRras) were prepared from exponentially growing or confluent cultures and plated in 60 
mm dishes containing 5 ml medium. Three cell inoculum levels, each in triplicate, were 
plated for each radiation dose delivered. Cells were allowed to attach for four hours and 
were then irradiated with 0 to 4.0 Gy at room temperature using a 5 MeV or 6 MeV accel­
erator. After irradiation the cultures were returned to the incubator for colony formation. For
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Three different methods for calculating survival from clonogenic assays.
Table 1
Method 1 Survival based on pooled plating efficiency data from all inoculum levels.
Method 2 Survival based on lowest inoculum level per dose (linear data).
Method 3 Survival based on equal inoculum levels at all doses.
human fibroblasts, a slightly different protocol was used. Early passage fibroblasts, both in 
confluent and exponential growth, were irradiated with 0-3.0 Gy and then seeded in 100 mm 
dishes, using 3-5 different cell inoculum levels, each in duplicate. After 2-3 weeks of incu­
bation, fibroblast colonies were fixed, stained and counted.
Three different methods of selecting data for survival analysis were evaluated, as 
described in Table 1.
Results
Plating efficiency
The data from the 22 early passage human fibroblast strains were pooled in order to 
examine the relationship between the number of cells seeded and plating efficiency. The 
results for control and after three different radiation doses are shown in Figure 1. As can be 
seen, there appears to be a linear relationship between the number of cells inoculated and 
colony number until a level of approximately 70 colonies per 100 mm dish is reached. But 
as the number of cells per dish increases, the total number of colonies does not increase at 
the same rate. This change at 70 colonies/dish occurs for both irradiated and unirradiated 
cells. In the human melanoma cell lines, the relationship between cells inoculated and 
colony number becomes non-linear after 40-50 colonies per dish (data not shown). On the 
other hand, a CHO cell line (AA8) and an adenocarcinoma cell line (Clone A) do not show 
this phenomenon. In these cases, colony number and inoculum size have a linear relation­
ship no matter how many cells are inoculated. (Figure 2)
To determine whether this apparent inhibition of colony formation was due to the sur­
face area available per cell seeded, the PE data from figure 1 was plotted against the culture 
surface available for each cell (Figure 3). The plating efficiency increases with increasing 
area, but it reaches a plateau after 150 mm2/cell, which is only 52 cells in a 100 mm cul­
ture dish. Similar results were found for the melanoma cell lines IGRneo, IGRmyc and 
IGRras (data not shown).
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Figure 2
The Chinese ham ster cell line, 
CHO-AA8, has a constant p la t­
ing efficiency, that is independ­
ent o f  the number o f  cells inocu­
lated.
Plating efficiency versus surface per cell
0 100 200 300 400
mm2 per cell
Figure 3
The relationship between culture 
surface area available p e r  cell 
and plating efficiency is shown. 
The data were taken from the 
unirradiated cells in Table 1.
Radiation experiments
Since measurements of cell sensitivity to cytotoxic treatments are based upon accurate 
PE measurements, PE artifacts caused by different cell seeding densities must be properly 
controlled. The neo-, c-myc and N-ras transfectants of the human melanoma cell line 
IGR39D and normal human skin fibroblasts were irradiated with graded doses from 0-4.0
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Gy. Plates were seeded with 3 different inoculum levels at all radiation doses and the plat­
ing efficiencies were determined. Since different plating efficiencies were observed at dif­
ferent inoculum levels after the same dose of irradiation, selecting data for survival curves 
is problematical. Therefore, survival curves were calculated by three different methods, but 
all according to the equation: elog S = -aD-6D2. First, survival was calculated by pooling 
all the data obtained from the experiments (Table 1, method 1 and Table 2,1). Second, sur­
vival was calculated while only taking into account plating efficiencies that show a linear 
relationship with the numbers of cells seeded (i.e. low inoculum levels, Table 1, method 2 
and Table 2, 2). The survival curves as based on these data are shown in Figure 4, where 
S33 (a human fibroblast line) is taken as an example. It can be seen that data from the low­
est inoculum had the highest levels calculated survival, while plating efficiencies taken from 
the highest inoculum level lead to lower estimates of survival. When using pooled data or 
high inoculum levels, the lowest survival was calculated, probably due to an underestima­
tion of plating efficiency. From this we conclude that only data derived from the range 
where a linear relationship between plating efficiency and colony formation exists leads to 
the best estimation of survival.
In the third method, survival was calculated by comparing plating efficiencies from an 
equal level of inoculum for untreated and treated cells. As cell killing is higher after larger 
doses of irradiation, these data can only be obtained for low radiation doses; otherwise the
Table 2
SF2 results calculated from each o f the 3 methods listed in Table 1.
SF2
1 2 3
IGRneo 0.57 0.64 0.56-0.81
IGRmyc0.52 0.48 0.46-0.63
IGRras 0.38 0.39 0.43-0.57
BAR1 0.16 0.24 n.a.a
S33 0.4 0.45 n.a.
Results of SF2 as calculated from the 3 methods listed in Table 1.
Method 1 Survival based on pooled plating efficiency data from all inoculum levels. 
Method 2 Survival based on lowest inoculum level per dose (linear data).
Method 3 Survival based on equal inoculum levels at all doses. 
a Not available
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Figure 4
Survival curves o f  fibroblast line 
S33 , after survival was calcu­
lated from  po o led  data, low  
inoculum levels or high inocu­
lum levels.
number of colonies after treatment will be too low to be statistically significant. The data 
were not available for BAR1 and S33. The purpose of this approach was to determine if it 
is the total numbers of cells seeded that contribute to plating efficiency reduction or the 
absolute number of surviving cells. Results for the cell lines IGRneo, IGRmyc and IGRras 
are listed in Table 2, Row 3, and it can be seen that different surviving fractions are calcu­
lated, depending on the inoculum level chosen. If PE depends upon the total number of 
seeded cells, survival would be constant. From this we conclude that it is the absolute num­
ber of surviving cells and not the total number of seeded cells that contribute to the cell den­
sity dependent plating efficiency.
We investigated whether the growth rate of the cells at the moment of inoculation could 
influence this phenomenon. As it occurs both in the case when cells were taken from expo­
nential growth or confluence, the plating efficiency was dependent on seeding density.
Discussion
The validity of clonogenic assays is dependent upon plating efficiency being inde­
pendent of the different numbers of cells inoculated in each experiment. However, we have 
found for a number of cell lines, that plating efficiency is dependent upon the cell seeding 
density within the critical range of cell numbers used in survival assays. This appears to be
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true for human cell lines of various origins, including malignant melanoma, with and with­
out transfected oncogenes, and for normal skin fibroblasts. At relatively high inoculum lev­
els, plating efficiency was found to be highly dependent on the cell concentration placed 
into culture. Since we do not know the mechanism responsible for these observations, it is 
necessary to include controls to correct for this problem [3,4]. This is accomplished by 
using five inoculum levels for each radiation dose and then use only those data in which a 
linear relationship between the numbers of cells inoculated and colonies formed is appar­
ent. This same phenomenon was also observed in rodent cell lines (3T3 fibroblasts, data not 
shown) and in both treated and untreated cells. By testing three different methods of select­
ing data from clonogenic assays, we illustrate both the importance of examining each cell 
line for this problem and also methods to use controls to be certain the survival data are 
valid. That is, simply, to use only those data which have been shown to have a linear rela­
tionship between cell number and PE.
By taking into account only equal inoculum levels, we concluded that it is the absolute 
number of surviving cells that contribute to the inhibition of colony formation. Therefore, 
the bending point, i.e. the number of colonies that is no longer linearly related to the num­
ber of seeded cells, is not always the same and must be determined experimentally. When 
radiation experiments are performed, the exact number of survivors is not known before­
hand, so in case of cell density dependent plating efficiency, it is obligatory to validate plat­
ing efficiency measurements by inoculating a range of different cell numbers.
The discovery of a non-linearity of colony formation is not new. Eliason et al [2] report­
ed that primary cultures from human tumor biopsies, exhibit plating efficiencies that are 
dependent on cell seeding densities. In 1983, Meyskens et al [5] published that murine 
melanoma cells have a non-linear relationship between plating efficiency and cell numbers. 
It appeared that only colonies smaller than 70 ^m exhibit a linear relationship. These 
authors also showed that survival (after treatment with DTIC) can be erroneously higher 
than controls at low toxicity level.
Conclusion
Our observations point out the importance of standardizing clonogenic assays when 
testing for cell sensitivity to ionizing radiation or chemotherapeutic drugs in vitro. Cell den­
sity dependent plating efficiency differences are common, unpredictable, and can lead to an 
incorrect interpretation of survival data.
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Chapter 8
Summary and discussion
The theme of this thesis explores the contribution of oncogenes to radiation response of 
malignant cells. Proto-oncogenes play a role in DNA damage recognition, the regulation of 
checkpoints, and are often involved in DNA damage repair [13,25,26,47], for example after 
ionising radiation [3,5,29] and cell cycle control [14]. They do not contribute to malignant 
development under normal conditions. In the case of alteration by mutation or overexpres­
sion by gene amplification, proto-oncogenes are called oncogenes. Oncogenes deregulate 
basic molecular pathways in the cell and can cause cancer. As proto-oncogenes are involved 
in cell cycle regulation and DNA damage repair after radiotherapy, it is possible that onco­
genes can modify the radiation response, thereby affecting the treatment outcome. Therefore 
it is of interest to understand the effects of oncogenes on radiosensitivity.
Firstly, we investigated whether oncogene expression in malignant cells alters radiosen­
sitivity and secondly which mechanisms play a role. Both in vitro data using a human 
melanoma cell line, and clinical data collected from patients with oesophagus carcinoma 
treated by high dose radiotherapy provided material for this thesis.
Chapter 1 starts with a short introduction to basic radiobiology. This is indispensable 
to interpret the in vitro data from the clonogenic and cell cycle assays. The function of onco­
genes in normal and tumour cells is explained and how they may play a role in the radia­
tion response and cell cycle regulation. The last part of the chapter summarises the layout 
of the thesis and which questions served as a guidance to fulfil this study.
In Chapter 2 we describe how oncogene transfection affected the radiation response of 
a human melanoma cell line. A human melanoma cell line (IGR39D) with normal expres­
sion of MYC and without mutated NRAS was transfected with either oncogene or both. 
NRAS contained a mutation in codon 61 (NRAS 61-arginine); MYC was brought to overex­
pression by transfection. We showed that the survival after single dose irradiation was 
decreased after transfection with MYC or NRAS. When both oncogenes were transfected 
into the parental cell line, survival was reduced only in the first part of the survival curve 
(up to 4 Gy), after which it resembled the parental line.
At first glance this result is in contrast with early literature describing an increased radi­
ation resistance after transfection with the oncogene H-ras in rodent cell lines. The most 
likely explanation is that our melanoma cell line differed from the cell lines that were used 
for the original papers, correlating oncogene expression with radiation response. The cell 
lines used in the early nineties were rat embryonic fibroblasts. These non-malignant cell 
lines probably had no oncogene activation, a wild type p53 status and last but not least, 
expressed proto-oncogenes necessary for embryonic development.
p53 is involved both in G1 and G2 delay and mutated p53 may overrule the effect of
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other oncogenes that are involved in radiation response. Although no consensus exists 
whether p53 by itself can be held responsible for altered radiosensitivity (except in lym­
phocytes systems) it may influence the expression and function of other oncogenes [12]. 
The melanoma cell line we used was of human origin and malignant. We regarded this as a 
better reflection of the clinical situation of human tumours with activation of oncogenes, 
which may be involved in the radiation response. The p53 status as detected by polymerase 
chain reaction-single strand conformation polymorphism (PCR-SSCP) showed that this 
gene was truncated in the parental cell line we used. Therefore this cell line should proba­
bly be considered p53 null.
Cellular response to ionising radiation is complex and involves multiple pathways. An 
oncogene-related effect might be unnoticed if an alternative pathway annuls its effect, so 
that in the cell line used, this oncogene status does not affect the phenotypic features of 
radiosensitivity. Furthermore, an effect on radiation response can only become clear if the 
whole pathway downstream this oncogene is intact.
In summary, the influence of one single oncogene on radiation response will depend on 
the status of the total complex of pathways involved in DNA damage recognition, repair and 
cell cycle regulation.
In the literature on rodent material, oncogene-related increased radioresistance was 
accompanied by a longer G2 delay after ionising radiation. This phenomenon was used as 
an explanation for increased survival after radiotherapy. In Chapter 3 we describe cell cycle 
effects after radiotherapy of the parental and the ^A^-transfected melanoma cell lines. Cells 
were labelled with propidium iodide to measure the total DNA content, and with BrdUrd to 
determine the progression of cells through S phase. By looking at the DNA content at time 
intervals after radiation, the accumulation of cells in G2 was established. It was found that 
the G2 delay in the NRAS-containing cell line was prolonged. This is in part consistent with 
the literature. The data published earlier with rat embryonal fibroblasts also showed that 
cells transfected with H-ras had a longer radiation induced G2 delay than the parental cells 
[37]. However, in contrast with the conclusion from these authors, we could not confirm that 
prolonged G2 delay was a feature of radioresistance.
Beside the human origin and being derived from a malignant tumour, our cell lines dif­
fered from the rodent cell lines in p53 status. P53 is responsible for the Gx arrest after radi­
ation and more recently it has been suggested that p53 may also be involved in G2 delay 
[43] either directly or via p21/Cip1 [18]. Neither the parental melanoma cell line, nor the 
oncogene transfected daughter cell lines showed any G1 delay, due to mutations in the p53 
status.
The G2 checkpoint delays mitosis to check for DNA damage and allow for repair. DNA 
damage repair needs to be completed before mitosis starts in order to guarantee the gener­
ation of two normal daughter cells. Prolongation of G2 is therefore a manifestation of DNA
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damage and occurs after radiotherapy and other genotoxic insults. Altered regulation of 
cyclines and cycline dependent kinases are required to cause the G2 delay.
Attempts have been made to correlate the length of the G2 delay with radiation response 
and intrinsic radiosensitivity. If a correlation between radiosensitivity and the length of G2 
delay exists, it could be used as a predictive factor for the cellular response to radiotherapy. 
This topic is controversial; cells of ataxia telangiectasia (AT) patients, which are very 
radiosensitive, show prolonged G2 delay [2,10,31,32] suggesting a correlation between the 
duration of G2 delay and radiosensitivity, while in rodent systems, prolonged G2 delay after 
oncogene transfection was used as an explanation for oncogene induced radioresistance. For 
both phenomena different explanations can be put forward. First there is the importance of 
an intact G2 checkpoint. When the G2 checkpoint is normal, prolonged G2 delay is an 
expression of increased DNA damage, which should correlate with radiosensitivity. On the 
other hand can prolonged G2 delay allow for increased DNA repair resulting in increased 
survival (radioresistance). Permanent arrest in the G2 phase is one form of clonogenic death. 
Malfunctioning of the checkpoint, leading to an inadequate G2 delay, would leave DNA 
damage unrepaired, resulting in increased kill. This so-called mitotic catastrophe is anoth­
er form of clonogenic death. So, without knowledge about the intactness of the G2 check­
point and other cell cycle regulating mechanisms, the relation ship between G2 delay and 
radiation response cannot properly be interpreted. The fact that G2 delay is dose dependent 
(and corresponds with reduced survival), also suggests that the duration of the G2 is a reflec­
tion of DNA damage and more likely to be a feature of radiosensitivity.
By labelling cells with BrdUrd just before irradiation, progression through the S phase 
could be followed. After 5 Gy we found no significant S phase delay. It appeared, however, 
that the S phase shortly after irradiation was slightly reduced, but the total duration of the 
S-phase was not impaired, as expected from previous studies [27]. There was no difference 
in S phase duration between the parental and the NRAS transfected cell line.
In conclusion, based on the literature and our own experiments, we found there is no 
basis to assume a direct correlation between G2 delay and radiosensitivity. Therefore we 
conclude that the effect of ionising radiation on G2 delay is not correlated with radioresis­
tance in general but depends on the system under investigation. G2 delay cannot be used as 
a predictor for radiosensitivity.
The role of p53 in the radiation response after radiotherapy is explored in Chapter 4. 
As mentioned earlier, wildtype p53 plays a role in cell division, cell cycle regulation and the 
integrity of the genome. It is important for the G1 arrest and involved in apoptosis induction 
after radiotherapy. The reduction in apoptosis when p53 is mutated has been put forward as 
an explanation for radioresistance. However, whether apoptosis is a sign of radiosensitivity 
is controversial [6,48]. Apoptosis may have a more important impact on fractionated radio­
therapy than on single dose radiation [42]. Furthermore, p53 is not the only determinant for
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apoptosis. p53 independent stress responses, regulating cell growth, should not be over­
looked. Apoptosis and G1 arrest can also occur without activation of p53 or WAF/CIP1 
expression [20]. The p53 response differs in different normal tissues and does therefore not 
always have the same effect on radiation response [36]. Some papers have correlated mutat­
ed p53 with an increased radioresistance and an increased resistance to cytotoxic therapy 
[17,30,33-35] while other paper could not confirm this [4,6,9,16,28,49].
In this clinical study, we questioned whether p53 status played a role in the local con­
trol of oesophagus carcinoma treated by high dose radiotherapy only. A retrospective study 
is described which was performed on material of patients with oesophagus carcinoma who 
had been treated by radiotherapy exclusively. We investigated the role of p53 on local con­
trol and the impact on survival. Biopsy material was available of 69 patients prospectively 
followed in a non-randomised study. Paraffin embedded tissue blocks were used to deter­
mine the p53 status by immunohistochemistry. Expression of p53 was correlated with over­
all survival, local recurrence free survival and the occurrence of distant metastases. The 
overall survival was significant higher for patients with negative p53 staining (wild type 
p53). Local disease free survival did not correlate with p53 status. Based on these data we 
could not conclude that p53 status is associated with altered radiation response. The metas- 
tases-free survival was worse for mutated p53 tumours.
As discussed previously, the status of one single oncogene can not determine radiosen­
sitivity. Preferably the presence of all oncogenes that are related to survival after ionising 
radiation should be considered; this still remains difficult at the present time. Another 
explanation why no direct correlation between local control (a measure for radiosensitivity) 
was found, may be the staining method of p53. Not all mutations lead to detectable over­
expression by immunohistochemistry. Furthermore the influence of mutated p53 on 
radiosensitivity is tumour type dependent and different mutations may have different impact 
on radiosensitivity [11].
Radiotherapy is aimed to provide local-regional control. Local control is important and 
reduces the risk of distant metastases [40,41,44]. If local control cannot be obtained, the risk 
of distant metastases is increased. Oncogenes are involved in the radiation response. Since 
radiosensitivity may be affected by oncogenes, we hypothesise that oncogene expression 
may also have an impact on the occurrence of distant metastases. This may either be by a 
direct effect on metastatic behaviour, or an indirect effect via mechanisms involved in the 
radiation response and altered local tumour control.
When we discovered that p53 expression correlated with increased distant metastases in 
a group of patients with oesophagus carcinoma, we also studied e-cadherin expression, 
another oncogene involved in the development of distant metastases. The results are given 
in chapter 5. In this chapter a correlation between e-cadherin and a range of pre-treatment 
parameters, including p53 was looked at. No relation could be found between de different
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parameters studied. With regard to treatment outcome we found a relation between e-cad- 
herin expression pattern and the occurrence of distant metastases. When an aberrant stain­
ing pattern for e-cadherin was found, the risk of distant metastases was reduced.
In general, it is believed that normal e-cadherin expression prevents the occurrence of 
distant metastases, which is in contrast with our findings. However, our data are in agree­
ment with a paper on pancreatic tumours where intact e-cadherin was associated with an 
increased risk on distant metastases. The explanation given was that the cells needed close 
contact, provided by normal e-cadherin expression, in order to establish metastases [23].
The rationale to connect radiation response, oncogene expression and metastases is 
based on literature from the seventies, suggesting that radiotherapy can alter metastatic 
behaviour of tumours [46] and more recent literature, showing that radiation can upregu- 
late the expression of e-cadherin [1,19].
A possible correlation between e-cadherin and p53 was first suggested in a study with 
p53 deficient mice, which developed skin tumours with altered expression of e-cadherin [8] 
and in a clinical study correlating p53 and e-cadherin in a series of breast carcinomas [7]. 
The explanation is that a relationship between p53 and e-cadherin could involve p-catenin. 
p-catenin promotes the accumulation of transcriptionally active p53 by interference with 
degradation of p53. This is probably an indirect effect since a decrease in e-cadherin 
enhances the release of p-catenin into the cytosol and nucleus and this may trigger p53 sta­
bilisation [15].
The influence of p53 on the occurrence of distant metastases does not necessarily 
involve catenins and cadherin only. Many more metastasis-related genes are under the influ­
ence of p53 like matrix metalloproteinase (MMP), cathepsin D, thrombospondin-1 [45]. 
Whether these oncogenes have an impact on distant metastases in tumours treated by radio­
therapy is not known.
Last but not least, we must take into account all the limitations of the methods used. In 
chapter 6, four different antibodies were used to evaluate their predictive power detecting 
p53 expression. Detection of p53 using the antibody DO7 correlated significantly with over­
all survival and distant metastases free survival. For local recurrence free survival no level 
of significance was reached. The use of the other 3 antibodies all showed the same trend 
with regard to distant metastases, however no significance was ever reached. The use of 
multiple antibodies did not increase the predictive value of DO7 [24].
The pitfalls of clonogenic assays are described in chapter 7. We found that for a num­
ber of cell lines the density of the seeded cells had an impact on plating efficiency; when 
too many cells were seeded, plating efficiency was inhibited leading to an underestimation 
of the plating efficiency. This could occur for untreated as well as for treated dishes. It had 
hardly been noticed in literature [21,38] that the survival fraction could be underestimated
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due to this, leading to underestimation of SF2.
We therefore recommend that the phenomenon of cell density dependent plating effi­
ciency should always be tested before results from such assays are interpreted.
Conclusions
After one decade and many papers on the correlation between oncogene expression and 
radiation response, no clear answer has been given whether this is relevant for radiothera­
py. The participation of oncogenes in the response after ionising radiation is clearly com­
plex. When an oncogene has a role in DNA damage recognition or repair, or cell cycle reg­
ulation, an influence on radiation response can be anticipated. Today the knowledge of the 
expression status of one single oncogene is not considered enough to predict outcome after 
radiotherapy, as the contribution of a single oncogene in the response to radiotherapy can 
never be seen as a sole factor. [5]. We conclude that due to the complexity of interactions 
of many mechanisms involved in radiation response, the determination of a limited number 
of oncogenes can not be used to predict the outcome of radiotherapy
In vitro experiments have established that oncogenes can influence radiosensitivity but 
this depends on the cell line under study. The best example so far is p53. Whether p53 leads 
to apoptosis or Gx arrest after ionising radiation depends on the tissue that is looked at 
[11,22,39]. Consequently, mutations in p53 cannot predict eventual alterations in radiosen­
sitivity.
With regard to cell cycle control and ionising radiation, the correlation between G2 
delay and radiation response remains unclear, as the correct interpretation of the role of the 
G2 delay is not exactly defined yet.
Another interesting link with radiation response is the occurrence of distant metastases. 
From clinical research it is known that local control reduces the development of distant 
metastases. Different mechanisms may relate radiation responses and metastatic pattern. 
First a common factor influencing both radiosensitivity and the risk on distant metastases 
may exist. Second, the influence of radiotherapy by itself on the occurrence of distant 
metastases (eventually via oncogene pathways) deserves further study.
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Samenvatting en discussie
De effecten van oncogenen op de respons van maligne cellen na bestraling zijn onderwerp 
van studie voor dit proefschrift. Proto-oncogenen spelen een rol bij de herkenning van DNA 
schade en de regulatie van controle punten tussen de verschillende fasen van de cel cyclus 
(checkpoints). Zij zijn vaak betrokken bij het herstel van DNA schade [13,25,26,47], zoals 
bijvoorbeeld na bestraling [3,5,29] en de gepaard gaande effecten op de celcyclus [14]. 
Onder normale omstandigheden dragen proto-oncogenen niet bij aan maligne ontaarding 
van cellen. In geval van verandering door mutatie of overexpressie door genamplificatie, 
worden proto-oncogenen oncogenen genoemd. Oncogenen kunnen allerlei enzymatische 
routes in de cel verstoren en op die manier mede verantwoordelijk zijn voor het ontstaan van 
kanker. Aangezien proto-oncogenen betrokken zijn bij de regulatie van de cel cyclus en 
reparatie van DNA schade na radiotherapie, is het mogelijk dat oncogenen de reactie na 
radiotherapie veranderen. Daarom is het nodig meer inzicht te krijgen in de effecten van 
oncogenen op de stralen gevoeligheid van cellen.
Ten eerste werd onderzocht of oncogen expressie in kwaadaardige cellen de stralen 
gevoeligheid van deze cellen verandert en vervolgens welke mechanismen hierbij een rol 
spelen. Zowel in vitro data van een humane melanoom cellijn en klinische data, verzameld 
van patiënten met oesophaguscarcinoom, behandeld met radiotherapie, leverden het materi­
aal voor dit proefschrift.
Hoofdstuk 1 start met een korte introductie in de radiobiologie. Dit is onmisbaar om in 
vitro data van clonogene assays en mechanismen van cel cyclus regulatie te begrijpen. De 
functie van proto-oncogenen wordt besproken en hoe zij betrokken kunnen zijn bij de reac­
tie op bestraling en de regulatie van de celcyclus. Het laatste deel van dit hoofdstuk vat het 
onderzoek samen en welke vragen wij ons hierbij gesteld hebben.
In Hoofdstuk 2 wordt beschreven hoe oncogen-transfectie de radiatie respons van een 
humane melanoom cellijn beïnvloedt. Een humane melanoom cellijn (IGR39D) met nor­
male expressie van MYC en zonder gemuteerd NRAS werd getransfecteerd met elk oncogen 
afzonderlijk of beide. Het NRAS oncogen bevat een mutatie in codon 61 (NRAS 61-argi­
nine); MYC werd tot overexpressie gebracht middels transfectie. Aangetoond werd dat de 
overleving na eenmalige bestraling was verminderd na transfectie met MYC of NRAS. 
Wanneer beide oncogenen werden getransfecteerd in de parentale cellijn was de overleving 
weliswaar verminderd maar alleen in het eerste deel van de overlevingscurve tot 4 Gy. 
Daarna was de overleving hetzelfde die van de parentale lijn.
Op het eerste gezicht lijken deze resultaten in contrast met de vroege literatuur welke 
een verhoogde radioresistentie beschreef van knaagdier cellijnen die getransfecteerd waren 
het oncogen H-ras. De meest waarschijnlijke verklaring hiervoor is dat onze melanoom cel­
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lijn verschilt van de cellijnen die gebruikt werden voor de oorspronkelijke literatuur, waarin 
oncogen expressie in verband gebracht werd met de reactie op bestraling. De cellijnen die 
oorspronkelijk werden gebruikt waren rat embryonale fibroblasten. Deze niet maligne cel­
lijnen hadden waarschijnlijk geen oncogen activatie, bevatten een wild type p53 en bracht­
en proto-oncogenen tot expressie nodig zijn voor embryonale ontwikkeling. 
p53 is betrokken zowel bij de G1 als de G2 delay en gemuteerd p53 zou het effect kunnen 
overschaduwen van andere oncogenen welke betrokken zijn bij de respons op radiothera­
pie. Er bestaat geen consensus of gemuteerd p53 zelf verantwoordelijk kan zijn voor veran- 
derderde stralen gevoeligheid (behalve in lymfocyten systemen), maar het zou wel de 
expressie en functie van andere oncogenen kunnen beïnvloeden [12]. De melanoom cellijn 
door ons gebruikt, was van humane origine en maligne. Wij beschouwden dit als een betere 
weergave van de klinische situatie van humane tumoren met activatie van oncogenen welke 
betrokken kunnen zijn bij de reactie op radiotherapie. Polymerase chain reaction-single 
strand conformation polymorphisme (PCR-SSCP) toonde aan dat p53 in onze parentale cel­
lijn was getrunceerd. Daarom beschouwden wij onze cellijn als p53 nul type.
De cellulaire respons op bestraling bestaat uit meerdere stappen. Een oncogen gerela­
teerd effect zou ongemerkt kunnen blijven als een alternatieve route dit effect opheft, waar­
door op het fenotype van stralengevoeligheid niet verandert. Een eventueel effect van een 
oncogen op response na radiotherapie kan alleen worden opgepikt als de alle volgende stap­
pen in de reactie op radiotherapie intact zijn. De invloed van een enkel oncogen op de radi­
atie respons is afhankelijk van het totale complex van reacties betrokken bij herkenning en 
reparatie van DNA schade en de regulatie van de celcyclus.
In de literatuur over cel lijnen van knaagdieren ging oncogen gerelateerde radioresistentie 
samen met een toegenomen verlenging van de G2 fase (G2 delay). Dit fenomeen werd 
gebruikt als een verklaring voor verhoogde overleving na radiotherapie. In Hoofdstuk 3 
worden de celcyclus effecten van de parentale en de RAS getransfecteerde melanoom celli­
jnen na radiotherapie beschreven. Cellen werden gelabeld met propidium iodide om de 
totale DNA inhoud te meten en met BrdUrd om de progressie van de cellen door de S fase 
te volgen. Door de DNA inhoud vast te stellen op verschillende tijdsstippen na bestraling 
werd de stapeling van cellen in de G2 gemeten. De G2 delay in de RAS bevattende cellijn 
was verlengd. Dit is deels in overeenstemming met de literatuur. De eerder gepubliceerde 
data met rat embryonale fibroblasten toonde ook dat cellen die getransfecteerd waren met 
H-ras een langere G2 delay hadden na bestraling dan de parentale cellijnen [37]. In contrast 
met de conclusie van deze auteurs, konden wij echter de verlengde G2 delay niet in verband 
brengen met radioresistentie.
Naast het feit dat onze cellen van humane origine en afkomstig van een maligne tumor 
waren, verschilden onze cellijnen met die uit de literatuur, in p53 status. P53 is een proto­
oncogen, verantwoordelijk voor de G1 arrest na bestraling en is ook in verband gebracht met
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de G2 delay [43] hetzij via directe beïnvloeding of indirect via p21/Cip1 [18]. Noch de 
parentale melanoom cellijn, noch de oncogen getransfecteerde dochter cellijn tonen enige 
G1 delay hetgeen wordt toegeschreven aan mutaties in p53.
Het G2 checkpoint vertraagt de mitose zodat DNA schade kan worden opgespoord en 
gerepareerd. De reparatie van schade aan het DNA moet voltooid zijn voor de mitose begint 
om het ontstaan van twee normale dochterstellen te waarborgen. Verlenging van de G2 fase 
is daarom een uiting van DNA schade en treedt op na radiotherapie en andere genotoxische 
schade. Veranderende regulatie van cyclines en cyclinen afhankelijke kinases zijn verant­
woordelijk voor deze G2 delay.
Er zijn pogingen ondernomen om de duur van de G2 delay te correleren met de reactie 
op radiotherapie en de intrinsieke radiosensitiviteit. Indien er een correlatie tussen de 
stralengevoeligheid en de lengte van de G2 delay bestaat, dan zou deze gebruikt kunnen 
worden om de cellulaire respons op radiotherapie te voorspellen. Dit onderwerp is contro­
versieel; cellen van ataxia telangiectasia (AT) patiënten die erg gevoelig zijn voor bestral­
ing, vertonen een verlengde G2 delay [2,10,31,32], hetgeen een correlatie suggereert tussen 
de duur van de G2 delay en stralengevoeligheid, terwijl in knaagdier cellijnen, verlengde G2 
delay juist werd gebruikt als een verklaring voor oncogen geïnduceerde radioresistentie. 
Voor beide effecten bestaan verschillende verklaringen. Allereerst is het van belang dat het 
G2 checkpoint intact is. Wanneer het G2 checkpoint normaal functioneert, betekent ver­
lengde G2 fase vaststelling en reparatie van meer DNA schade, hetgeen past bij 
stralengevoeligheid. Een verlengde G2 delay kan ook gelegenheid bieden voor betere 
reparatie van DNA schade, met als gevolg hogere overleving (stralenresistentie). 
Permanente arrest in de G2 fase is één van de vormen van clonogene dood. Wanneer het 
checkpoint niet of onvoldoende functioneert, hetgeen een niet optimaal G2 delay tot gevolg 
heeft, kan de mitose ingezet worden met DNA schade welke niet voldoende gerepareerd is, 
resulterend in toegenomen cel dood. Deze zogenoemde mitotische catastrofe is ook een 
vorm clonogene dood. Het is onmogelijk om zonder kennis over het al dan niet goed func­
tioneren van het G2 checkpoint en andere celcyclus regulerende mechanismen, een uitspraak 
te doen over de relatie tussen G2 delay en radiatie respons. Het feit dat de G2 delay dosis 
afhankelijk is (en correspondeert met verminderde overleving) suggereert dat de duur van 
de G2 delay een weergave is van de mate van DNA schade en daarmee hoogstwaarschijn­
lijk een uiting van stralengevoeligheid.
Door cellen juist voor de bestraling met BrdUrd te labelen kan de voortgang door de S 
fase worden gevolgd. Na 5 Gy vonden we geen significante S fase delay. Het leek er echter 
op dat de S fase kort na de bestraling enigszins vertraagd was maar de totale duur van de S 
fase was niet veranderd zoals uit voorgaande studies werd verwacht. Er was geen verschil 
in S fase duur tussen de parentale en de NRAS getransfecteerde cellijn.
In conclusie, gebaseerd op de literatuur en onze eigen experimenten vonden we geen 
onderbouwing voor een directe correlatie tussen de G2 delay en radiosensitiviteit. Daarom
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concluderen we dat het effect van straling op G2 delay niet gecorreleerd is met radiore- 
sistentie in het algemeen, maar afhangt van het systeem dat onderzocht wordt. G2 delay kan 
derhalve niet gebruikt worden als een voorspellende factor voor radiosensitiviteit.
De rol van p53 in de reactie op radiotherapie wordt behandeld in Hoofdstuk 4. Zoals 
eerder vermeld speelt wild type p53 een rol in de celdeling, celcyclus regulatie en het intact 
houden van het genetisch materiaal. p53 is essentieel voor de G1 arrest en is betrokken bij 
de inductie van apoptose na radiotherapie. Een verminderde apoptose in geval van mutatie 
in het p53 gen, is aangevoerd als een verklaring voor verminderde gevoeligheid voor 
bestraling. Of apoptose zelf een teken is van radiosensitiviteit blijft controversieel [6,48]. 
Mogelijk dat apoptose van meer belang is bij gefractioneerde radiotherapie dan na één 
enkele dosis [42]. p53 is niet de enige factor betrokken bij inductie van apoptose; Apoptose 
en G1 arrest kunnen ook optreden zonder activatie van p53 of WAF/CIP1 expressie [20]. De 
p53 respons varieert tussen verschillende normale weefsels en dit verklaart waarom p53 de 
reactie op radiotherapie verschillend kan beïnvloeden [36]. In sommige artikelen is een 
gemuteerde p53 status gecorreleerd met toegenomen radioresistentie en een toegenomen 
resistentie voor cytotoxische therapie [17,30,33-35], terwijl dit in andere publicaties niet het 
geval is [4,6,9,16,28,49].
In deze klinische studie werd onderzocht of de p53 status een rol speelt bij de locale 
controle van middels hoge dosis radiotherapie behandeld oesophagus carcinoom. Een ret­
rospectief onderzoek werd uitgevoerd op materiaal van patiënten met een oesophagus car­
cinoom behandeld met radiotherapie. We keken naar de invloed van p53 op locale tumor 
controle en de overleving. Biopsie materiaal was beschikbaar van 69 patiënten welke 
prospectief vervolgd waren in een niet gerandomiseerde studie. Paraffine weefselblokjes 
werden gebruikt om de p53 status door middel van immunohistochemie te bepalen. 
Expressie van p53 werd gecorreleerd met de overall survival, local recurrence free survival 
en het optreden van afstandsmetastasen. De overall survival was significant hoger voor 
patiënten met een negatieve p53 kleuring (wild type p53). Locale ziektevrije overleving was 
niet gecorreleerd aan de p53 status. Gebaseerd op deze data kon niet geconcludeerd worden 
dat de p53 status geassocieerd is met veranderde radiatie respons. De metastasevrije over­
leving was slechter voor p53 gemuteerde tumoren.
Opnieuw blijkt dat het niet mogelijk is om met de status van één enkele oncogen de 
radiosensitiviteit te voorspellen. Het liefst zouden alle oncogenen betrokken bij de reactie 
op radiotherapie in beschouwing moeten worden genomen. Dit is momenteel nog erg moeil­
ijk. Een andere mogelijkheid, waarom geen directe correlatie tussen locale controle (een 
maat voor radiosensitiviteit) en de p53 status werd gevonden, kan te maken hebben met de 
methode van p53 bepaling. Niet alle mutaties worden opgepikt door immunohistochemie. 
Verder kan de invloed van gemuteerd p53 op stralengevoeligheid afhankelijk zijn van het 
tumortype en verschillende p53 mutaties kunnen verschillende impact op de radiosensi-
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tiviteit hebben [11].
Radiotherapie is gericht op het verkrijgen van locoregionale controle. Locale controle 
is belangrijk en reduceert de kans op het ontstaan van afstandsmetastasen [40,41,44]. 
Oncogenen zijn betrokken bij de respons op radiotherapie. Aangezien radiosensitiviteit zou 
kunnen worden beïnvloed door oncogenen, vroegen wij ons af of oncogen expressie ook een 
invloed kan hebben op het ontstaan van afstandsmetastasen. Dit effect kan zowel direct zijn 
op het metastatische gedrag van tumorcellen of indirect via mechanismen die de 
stralengevoeligheid en locale controle beïnvloeden.
Na de bevinding dat p53 expressie correleerde met verhoogde afstandsmetastasen in 
patiënten met oesophaguscarcinoom, werd in deze groep de expressie van e-cadherin, een 
oncogen betrokken bij de ontwikkeling van afstandsmetastasen, bestudeerd. De resultaten 
zijn weergegeven in Hoofdstuk 5. In dit hoofdstuk wordt de relatie tussen e-cadherin en 
andere voor de behandeling aanwezige parameters en de uitkomst wat betreft overleving en 
lokaal recidief onderzocht. We vonden een relatie tussen e-cadherin expressie en het optre­
den van afstandsmetastasen. Wanneer e-cadherin abnormaal tot expressie kwam waren er 
minder afstandsmetastasen.
In het algemeen wordt aangenomen dat normale e-cadherin expressie het optreden van 
afstandsmetastasen voorkomt. Dit is in tegenspraak met onze bevindingen. Echter onze data 
zijn wel in overeenstemming met een artikel over pancreas tumoren waarin intact e-cadherin 
juist geassocieerd is met verhoogd kans op afstandsmetastasen. De verklaring hiervoor zou 
kunnen zijn dat cellen weliswaar niet te sterk aan elkaar vast moeten zitten om los te komen, 
maar normale e-cadherin expressie nodig hebben om afstandsmetastasen te vormen.
Het idee om reactie op bestraling, oncogen expressie en afstandsmetastasen met elkaar 
in verband te brengen, is gebaseerd op literatuur van de vroege 70 jaren waarin gesug­
gereerd wordt dat radiotherapie het metastatisch karakter van tumoren kan beïnvloeden [46] 
en meer recente literatuur welke aantoont dat bestraling de expressie van e-cadherin kan 
aanschakelen [1,19].
Een mogelijke correlatie tussen e-cadherin en p53 werd gesuggereerd in een studie met 
p53 deficiënte muizen die huidtumoren ontwikkelden met veranderde e-cadherin expressie 
[8] en in een klinische studie waarin p53 en e-cadherin gecorreleerd bleken te zijn in een 
serie mammacarcinomen [7]. Via b-catenin kan een mogelijke een relatie tussen p53 en e- 
cadherin worden verklaard. Vermindering van e-cadherin bevordert het vrijkomen van b- 
catenin in het cytosol en de nucleus en b-catenin bevordert de ophoping van transcription- 
eel actief p53 door afbraak van de p53 te verhinderen [15].
De invloed van p53 op het ontstaan van afstandsmetastasen hoeft niet alleen gerelateerd 
te zijn aan catenins en e-cadherin. Er zijn meer afstandsmetastasen gerelateerde genen 
welke onder de invloed van p53 staan, zoals matrix metalloproteinase (MMP), cathepsin D,
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thrombospondin-1 [45]. Of deze oncogenen van belang zijn bij het optreden van metastasen 
van tumoren die behandeld zijn met radiotherapie is nog niet bekend.
Van belang voor onderzoek zijn ook de beperkingen van de methoden die gebruikt wor­
den. In Hoofdstuk 6 werden 4 verschillende antibodies getest om de voorspellende waarde 
van p53 expressie te bepalen. De bepaling van p53 met gebruikmaking van het antibody 
DO7 correleerde significant met overall survival en optreden van afstandsmetastase vrije 
overleving. Voor het optreden van lokaal recidief werd geen significantie bereikt. Het 
gebruik van 3 andere antibodies toonde allemaal dezelfde trend met betrekking tot afs- 
tandsmetastasen maar geen van alle werd significant. Het gebruik van meerdere antibodies 
verhoogde niet de voorspellende waarde van DO7 [24].
De valkuilen van clonogene assays worden beschreven in Hoofdstuk 7. Wij vonden voor 
een aantal cellijnen dat de dichtheid van de uitgezaaide cellen een invloed had op de plat­
ing efficiency; wanneer te veel cellen worden uitgezaaid wordt de plating efficiency ver­
minderd, hetgeen kan leiden tot onderschatting van de plating efficiency. Dit kan zowel 
optreden voor behandelde als niet behandelde schaaltjes. Dit is nauwelijks beschreven in de 
literatuur [21,38]. Op deze manier kan de overlevingsfractie worden onderschat en daarmee 
de SF2. Wij raden daarom aan dat het fenomeen van cel dichtheid afhankelijke plating effi­
ciency altijd wordt getest voordat de resultaten van de assays worden geïnterpreteerd
Conclusies
Na 10 jaar en vele artikelen over de correlatie tussen oncogen expressie en de reactie op 
bestraling is er geen duidelijk antwoord op de vraag of dit relevant is voor de klinische 
radiotherapie. De betrokkenheid van oncogenen in de reactie na bestraling is heel complex. 
Indien een oncogen een rol heeft in de herkenning van DNA schade, reparatie van DNA 
schade of de celcyclus regulatie, lijkt een invloed op radiatie respons aannemelijk. 
Tegenwoordig is de kennis van de expressie van een enkel oncogen niet genoeg om de 
uitkomst na radiotherapie te voorspellen omdat een enkel oncogen deel uitmaakt van een 
complex geheel [5]. We concluderen dat ten gevolge van de vele interacties en mechanis­
men betrokken bij de reactie op radiotherapie, het niet mogelijk is om met een beperkt aan­
tal oncogenen te voorspellen hoe de uitkomst na radiotherapie zal zijn.
In vitro experimenten hebben aangetoond dat oncogenen de response op radiotherapie 
kunnen beïnvloeden maar de manier waarop hangt af van de cellijn. Het beste voorbeeld tot 
nu toe is het oncogen p53. Of p53 leidt tot apoptose of G1 arrest na bestraling hangt af van 
het weefsel dat bekeken wordt [11,22,39]. Daarom kan een mutatie in p53 niet een
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eventuele verandering in radiosensitiviteit voorspellen.
Met betrekking tot regulatie van de celcyclus na bestraling blijft de exacte relatie tussen 
G2 delay en radiatie respons onduidelijk omdat de correcte interpretatie van de rol van G2 
delay niet gedefinieerd is.
Een ander interessant verband met radiatie respons is het optreden van afstandsmetas- 
tasen. Uit klinisch onderzoek is bekend dat locale controle de ontwikkeling van afs- 
tandsmetastase vermindert. Verschillende mechanismen kunnen mogelijk een verband 
leggen tussen radiatie respons en metastaseringspatroon. Allereerst zou er een gemeen­
schappelijke factor kunnen bestaan die zowel de radiosensitiviteit als de kans op afs- 
tandsmetastasen beïnvloedt. Ten tweede dient de invloed van radiotherapie zelf op het optre­
den van afstandsmetastasen verder te worden onderzocht; het is niet ondenkbaar dat hierbij 
oncogenen betrokken zijn.
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